



This is a repository copy of *Teleost contributions to the understanding of mycobacterial diseases*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/149446/>

Version: Accepted Version

Article:

Hodgkinson, J.W., Belosevic, M., Elks, P.M. orcid.org/0000-0003-1683-0749 et al. (1 more author) (2019) *Teleost contributions to the understanding of mycobacterial diseases*. *Developmental & Comparative Immunology*, 96. pp. 111-125. ISSN 0145-305X

<https://doi.org/10.1016/j.dci.2019.02.011>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 **Teleost contributions to the understanding of mycobacterial diseases**

2

3 Jordan W. Hodgkinson¹, Miodrag Belosevic¹, Philip M. Elks^{2,3}, Daniel R. Barreda^{1,4,*}

4

5 From the ¹Department of Biological Sciences, University of Alberta, Edmonton, Alberta,
6 Canada, ²The Bateson Centre and ³Department of Infection, Immunity and
7 Cardiovascular Disease, University of Sheffield, Sheffield, South Yorkshire, United
8 Kingdom, and ⁴Department of Agricultural, Food and Nutritional Science, University of
9 Alberta, Edmonton, Alberta, Canada.

10

11

12

13

14

*Running title: *Teleost models of mycobacterial diseases*

15

16 (*) To whom correspondence should be addressed:

17 **Daniel R. Barreda**, Department of Biological Sciences, University of Alberta, Edmonton,
18 Alberta, Canada, T6G 2P5, Tel: (780) 492-0375, E-mail: d.barreda@ualberta.ca

19

20 **Key words**: Mycobacterial diseases, host-microbe interactions, teleost models, zebrafish,
21 comparative immunology.

22 **ABSTRACT**

23 Few pathogens have shaped human medicine as the mycobacteria. From
24 understanding biological phenomena driving disease spread, to mechanisms of host-
25 pathogen interactions and antibiotic resistance, the *Mycobacterium* genus continues to
26 challenge and offer insights into the basis of health and disease. Teleost fish models of
27 mycobacterial infections have progressed significantly over the past three decades, now
28 supplying a range of unique tools and new opportunities to define the strategies employed
29 by these Gram-positive bacteria to overcome host defenses, as well as those host
30 antimicrobial pathways that can be used to limit its growth and spread. Herein, we take a
31 comparative perspective and provide an update on the contributions of teleost models to
32 our understanding of mycobacterial diseases.

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **INTRODUCTION**

54 *Mycobacterium spp.* are Gram-positive, acid-fast staining, non-motile, non-spore
55 forming bacilli, further defined based on growth rate (rapid or slow growing) and
56 pigmentation (Runyon, 1959). The *Mycobacterium* genus consists of over 190 species
57 that occupy a broad range of ecological niches, and include serious human pathogens like
58 *M. tuberculosis* and *M. leprae*, as well as more innocuous soil-dwelling organisms. *M.*
59 *tuberculosis* has afflicted humans for approximately 70 000 years, and it is thought to
60 have killed more persons than any other microbial pathogen (Daniel, 2006). In 1865,
61 Jean-Antoine Villemin, a French military surgeon first demonstrated the infectiousness of
62 tuberculosis when he inoculated a rabbit with lung tissue from an individual that had died
63 of tuberculosis (Daniel, 2006). Eighteen years later, Koch identified the bacillus
64 responsible for TB and posited his famous postulates, setting a gold standard for
65 demonstrating etiology of infectious disease (Daniel, 2005; Koch, 1952). The Bacille de
66 Calmette et Guerin (BCG) vaccine was developed by serial passage of *Mycobacterium*
67 *bovis* in 1921, reducing the risk of acquiring TB by approximately 50% (Colditz et al.,
68 1994), although varying levels of effectiveness have been observed based on region,
69 genetic factors, exposure to other pathogens, and BCG culturing practices
70 (Venkataswamy et al., 2012). In 1944, the first effective antibiotic against tuberculosis
71 was introduced by Selman Waksam. Currently, there are a number of antibiotic therapies
72 with relatively high treatment success (approx. 85%) (Uplekar et al., 2006) though the
73 emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB
74 (XDR-TB) create new and urgent challenges in antibiotic therapy. Despite these advances,
75 it is estimated that one-third of the world's population is currently infected; the majority
76 of these cases remain asymptomatic, while approximately 9 million cases of active
77 tuberculosis (TB) and 1.3 million deaths are reported annually (Daniel, 2006; Herzog,
78 1998). Latent infections create a unique public health challenge as asymptomatic disease
79 reservoirs, particularly given ongoing issues with antibiotic resistance and prevalence of
80 human immunodeficiency virus (HIV) infections (Comstock et al., 1974; Vynnycky and
81 Fine, 2000).

82 Beyond human disease, the *Mycobacterium* genus has the capacity to infect a
83 wide range of domestic and wild animal species, including ruminants (*M. bovis*/*M.*

84 *paratuberculosis*), rodents (*M. microti*), birds (*M. avium*) reptiles (*M. smegmatis*)
85 amphibians and fish (*M. marinum*) (Hines et al., 1995). These pathogens are exquisitely
86 adapted to evade and co-opt host immune responses, allowing them to infect, replicate,
87 persist and transmit to new hosts. Disease typically manifests as granuloma formation, a
88 hallmark of mycobacterial infection, where aggregates of immune cells contain
89 pathogenic mycobacteria (Pagan and Ramakrishnan, 2015). In the case of *M. marinum*,
90 relative genetic relatedness to *M. tuberculosis* [80% of total coding sequences (CDS),
91 which share 85% amino acid similarity, in addition to 99.3% 16S rRNA sequence
92 similarity] has rendered fish models of infection useful for study of the tuberculosis-like
93 disease (Stinear et al., 2008). Fish disease models based on *M. marinum*, *M. chelonae* and
94 *M. fortuitum* infection have further helped our group to gain additional insights into
95 natural mycobacterial infections. Distinct bacterial growth patterns and granuloma
96 formation have been identified, although much remains to be learned about what
97 constitutes an effective host immune response for control of these infections.

98 This review summarizes key parameters in the immune response to mycobacterial
99 pathogens in mammalian and teleostean model systems, which highlight the complexity
100 of these host-pathogen interactions and impact the outcome of infection. Our goal is to
101 build on established insights derived from mammalian systems and offer novel points of
102 discussion based on recent findings using teleost fish models. We focus on two teleost
103 species, *Danio rerio* (zebrafish) and *Carassius auratus* (goldfish). Each provides unique
104 attributes for examination of mycobacterial infections. The zebrafish embryo was
105 developed for use as a model for developmental biology and has been used as such for
106 the last quarter of a century, primarily due to its external fertilisation and development,
107 visual transparency, and fecundity of the adults (Brittijn et al., 2009). This model offers
108 well recognized advantages based on unique molecular tools, genetic manipulation
109 capacity, and *in vivo* observation of immune cell transit and host-microbial interactions
110 early in development. Goldfish, on the other hand, has added opportunities because of the
111 greater number of cells available, well-established cultivation methodologies for primary
112 cells from adult fish, and protocols for *ex vivo* characterization of immune cell function.

113

114 **MYCOBACTERIUM SPP.**

115 Mycobacteria range in length between 1-10 μm long and 0.2-0.6 μm in diameter
116 (Gauthier and Rhodes, 2009; Jacobs et al., 2009). Mycolic acids, α -alkyl, β -hydroxyl
117 long-chain fatty acids, are the most abundant lipid in mycobacterial cell walls, making up
118 60% of the dry weight. Composition of mycolic acids are diverse within the
119 *Mycobacterium* genus and are used in conjunction with genomic approaches for
120 identification of species and strains (Portevin et al., 2014). Broadly, fast growers can
121 form colonies in a week or less, while slow growers take longer than a week to form
122 colonies on solid media. Molecular phylogenetic analysis has been used to further
123 distinguish and categorize species, which suggests a molecular basis for the growth speed
124 divisions (Saviola et al., 2006). Slow growing species include prevalent pathogens like *M.*
125 *tuberculosis*, *M. marinum*, *M. leprae* and *M. avium*. Faster growing mycobacterial species
126 are largely saprophytic, although *M. fortuitum* and *M. chelonae* have been shown to be
127 pathogenic, especially in fish and frog species and under nosocomial settings. As
128 mentioned, *M. marinum* and *M. tuberculosis* are very closely related from a
129 morphological and molecular standpoint.

130

131 TUBERCULOSIS

132 Tuberculosis (TB) is predominantly a lung disease, which accounts for 70% of
133 infection cases (Harisinghani et al., 2000). TB can be divided into two major patterns,
134 primary and post-primary TB. In a recent paper, Behr and colleagues (Behr et al., 2018)
135 suggested simplified terms to describe progression of TB in patients. Primary
136 tuberculosis is defined as the initial infection as evidenced by a positive tuberculin skin
137 test or a new positive interferon gamma release assay; active TB with evidence of
138 progressive disease of the lung; and tuberculous reactivity which is indirect evidence of
139 present or past infection with *M. tuberculosis* as inferred by adaptive immune response to
140 *M. tuberculosis* antigens (interferon gamma release assay, positive tuberculin test) in an
141 asymptomatic person (Behr et al, 2018). Primary infection is typically controlled by an
142 immunocompetent individual, although serious disease can manifest in children and
143 immunocompromised individuals (Hunter et al., 2018). The lesions in the lung that
144 develop during primary tuberculosis often heal, but despite the reduced pathology, the
145 infection is rarely sterilized and bacteria can persist for up to several decades as

146 subclinical infection, where mycobacteria remain within individual granulomas at a
147 variety of growth states (Paige and Bishai, 2010). Post-primary tuberculosis occurs
148 following first infection events, where systemic immunity has already been established
149 due to re-emergence of infectious bacilli that multiply and produce cavities in the lung
150 (Hunter, 2011). While the majority of post primary infections also spontaneously recover,
151 80% of the estimated 9 million yearly clinical cases of TB are the result of post primary
152 infections (Paige and Bishai, 2010). Ironically, immunocompetent individuals between
153 the ages of 15-40 are most likely to die from acute post primary TB (Cheeseman, 1952;
154 Lawn and Acheampong, 1999; Tucker and Dooley, 2018). Further, survivors of post
155 primary TB have an increased risk in contracting the disease again, rendering no
156 immunity to previous bouts of the disease (den Boon et al., 2007; van Rie et al., 1999).
157 Symptoms of active pulmonary TB include chest pain, coughing (with or without blood),
158 difficulty breathing, excessive sweating, fatigue, fever, weight loss, wheezing, cachexia
159 (Campbell and Bah-Sow, 2006). Active TB can also manifest as miliary disease,
160 meningitis, abdominal disease and sepsis (Jacob et al., 2009).

161

162 TELEOST MODELS OF MYCOBACTERIAL DISEASES

163 Although *M. tuberculosis* can infect most warm-blooded animals, traditional
164 laboratory infection models prove difficult in recapitulating human disease. Aerosol
165 transmission is not observed in non-primate models, there is limited capacity to observe
166 post-primary infection and disease, and only a few models (e.g. guinea pigs) generate
167 necrotic (caseous) granulomas (Basaraba and Hunter, 2017; Harper et al., 2012). As a
168 result, a range of animal models continue to be used in an effort to understand
169 mycobacterial disease, including non-human primates, mice, rabbits, guinea pigs, frogs,
170 and fish. The lack of a standardized model restricts easy integration of findings; however,
171 strengths within each of these models continue to yield important insights into the
172 mechanisms mediating immune responses to mycobacterial pathogens.

173 Teleosts are evolutionarily one of the first group of organisms to have both the
174 innate and classical adaptive arms of the immune response, both of which are key to the
175 pathogenesis of human TB. Moreover, *in vivo* fish models offer unique advantages over
176 traditional mammalian models of TB, as mice are not natural hosts of *M. tuberculosis* and

177 primate models are expensive and difficult to work with. Three *Mycobacterium* spp. are
178 most often used to elicit disease in fish: *M. marinum*, *M. chelonae* and *M. fortuitum*,
179 although an increasing number of species have been isolated from fish in recent years
180 (Gauthier and Rhodes, 2009). *M. marinum* is the closest related strain to human TB
181 complex, and as such is the most widely used in the laboratory setting. *M. marinum* so
182 closely resembles the human pathogen that it can also infect humans resulting in fish tank
183 granuloma. This disease occurs when *M. marinum* enters the extremities through
184 abrasions on the hand or arms, and produces granulomatous nodes (Petrini, 2006). The
185 pathology of fish tank granuloma is indistinguishable from cutaneous tuberculosis.

186 Piscine mycobacteriosis typically manifests as chronic disease, which may or may
187 not produce clinical signs both externally and internally. Externally, pathology includes
188 non-specific scale loss and dermal ulceration, pigmentation changes, spinal defects,
189 lethargy, ascites and emaciation (Jacobs et al., 2009; Leibovitz, 1980). Internal pathology
190 includes enlargement of the kidney, spleen and liver, as well as grey or white nodules on
191 internal organs (Gauthier and Rhodes, 2009). Similar to disease in mammals,
192 granulomatous inflammation represents a classical hallmark of infection. In fish,
193 granulomas can be found in multiple organs and tissues, and are highly variable in size
194 and organization (Jacobs et al., 2009). The relative relatedness to *M. tuberculosis*, as well
195 as the remarkably similar pathology in fish infections has rendered *M. marinum* a popular
196 surrogate model for human tubercular diseases.

197

198 *Mycobacterium marinum*

199 Infection with *M. marinum* was one of the first teleost disease models to be
200 adopted for increased understanding of the biology of mycobacterial infections, and has
201 become one of the most successful. Initial studies of infected zebrafish embryos and
202 adults, and were used to follow disease pathology over time. It was established that, on a
203 histopathological level, *M. marinum* infection in adults is a chronic granulomatous
204 disease that is hard to distinguish from human TB (Meijer et al., 2004; Meijer et al.,
205 2005). Infection of the one-day post fertilization zebrafish embryo led to the formation of
206 granuloma-like structures within just a few days, in the absence of adaptive immune cells
207 (Davis et al., 2002). The *M. marinum*/zebrafish model has also yielded insights into

208 mycobacterial virulence factors, drug tolerance and potential therapeutic targets.
209 Zebrafish infection experiments, for example, showed that WhiB6 modulates levels of
210 mycobacterial infection, granuloma formation, and dissemination (Chen et al., 2016a).
211 *M. marinum* strains lacking phthiocerol dimycocerosates (PDIMs) and structurally
212 related phenolic glycolipids (PGLs) were also avirulent and hypersensitive to
213 antibiotics (Yu et al., 2012). Multidrug-tolerant organisms have also been identified
214 soon after *M. marinum* infection driven through bacterial-macrophage interactions,
215 but appear susceptible to bacterial efflux pump inhibitors like verapamil (Adams et
216 al., 2011).

217 The emergence of transgenic lines labelling innate immune cell populations has
218 also paved the way for a tractable zebrafish/*M. marinum* embryo model in which the
219 innate immune response to mycobacterium infection could be investigated (Hall et al.,
220 2007; Walton et al., 2015) Ellett et al., 2011; Gray et al., 2011; Mathias et al., 2006;
221 Renshaw et al., 2006). Early morpholino knockdown oligonucleotide technologies also
222 uncovered important roles for many genetic and enzymatic systems in granuloma
223 formation, including cytokines (e.g., TNF α), cell signalling components (e.g., MyD88)
224 and cell matrix enzymes (e.g., MMP9) (Clay et al., 2008; van der Vaart et al., 2013;
225 Volkman et al., 2010). Furthermore, the ability to follow granuloma formation over time
226 using fluorescence timelapse microscopy has identified multiple rounds of phagocytosis
227 of *M. marinum* and cell death leading to the formation of hallmark granuloma structures,
228 cell behaviours that are likely to occur in and around the human lung upon infection
229 and/or TB reactivation, but require invasive imaging to observe in mammalian systems
230 (Hosseini et al., 2016). Importantly, findings from the zebrafish/*M. marinum* model have
231 been directly related to human genetic variation and TB disease (Tobin et al., 2012). With
232 the now widely adopted CRISPR-Cas9 system making it easier to knockout genes in
233 zebrafish, we expect many additional novel genetic findings in TB pathology from this *M.*
234 *marinum* model. In addition to the power of the zebrafish model, other fish models of *M.*
235 *marinum* include the goldfish allowing added flexibility for examination of responding
236 leukocyte populations and their antimicrobial functional responses *ex vivo* as well as *in*
237 *vivo* using adult fish (Grayfer et al. 2011; Hodgkinson et al. 2012; Grayfer et al., 2014).

238

239 *Mycobacterium abscessus*

240 The success of the zebrafish/Mm model has made zebrafish an attractive model
241 for other infectious diseases, and these include non-tuberculous mycobacterial diseases.
242 *Mycobacterium abscessus* is an important emerging human pathogen and is especially
243 associated with cystic fibrosis patients (Jonsson et al., 2007). An embryonic zebrafish
244 model of *M. abscessus* has helped to shed light on the innate immune mechanisms behind
245 the increased severity of a rough variant compared to the less severe smooth variant. These
246 distinct morphotypes have also been shown to contribute to different stages of infection
247 and display differential capacity to activate and respond to phagocyte antimicrobial
248 mechanisms (Malcolm et al., 2018). The rough morphotype also has a propensity to form
249 cords, large areas of extracellular bacteria too large to be phagocytosed by macrophages
250 or neutrophils. This cording leads to abscess formation, an important physiopathology of
251 *M. abscessus* infection, leading to greater larval death (Bernut et al., 2014). Additional
252 features of this important emerging mycobacterial disease including progression and fate
253 of *Mabs* infection, host and pathogen modulators of disease severity, and developing
254 opportunities for therapeutic intervention have recently been reviewed (Bernut et al.,
255 2017).

256

257 *Mycobacterium leprae*

258 Recently, a *Mycobacterium leprae* zebrafish model has been established to
259 understand the pathophysiology and the interplay between innate and adaptive immune
260 components in leprosy disease (Madigan et al., 2017b). *M. leprae*, is unique amongst
261 mycobacteria in that it causes peripheral neuropathy, leading to the devastating paralysis
262 and deformities associated with the disease. The initial nerve damage is caused by
263 macrophages activated through *M. leprae*-specific phenolic glycolipid 1 (PGL-1), rather
264 than neural interactions with the bacteria itself, highlighting a potential novel future
265 treatment opportunity (Madigan et al., 2017a).

266

267 **EARLY INFECTION EVENTS**

268 **Recognition**

269 Following inhalation of *M. tuberculosis* in humans, a variety of host phagocytes
270 localize to the site of infection, including resident macrophages, dendritic cells and
271 recruited neutrophils (Schlesinger, 1996). Host recognition of mycobacteria is mediated
272 through a number of specific pattern recognition receptors (PRR), Toll like receptors (i.e.
273 TLR2, TLR4 and TLR9), C-type lectin receptors (dectin-1, mannose receptor, and DC-
274 SIGN) and Nod-like receptors (NLRs) (Berrington and Hawn, 2007; Kleinnijenhuis et al.,
275 2011; Reiling et al., 2008). Not surprisingly, polymorphisms in PRR genes have been
276 shown to affect recognition of *M. tuberculosis*, corresponding to a disruption in
277 recognition events, as well as disease outcome (Caws et al., 2008), and MyD88 and
278 CARD9, master adaptors for TLRs and NLRs, are essential for host protection to *M.*
279 *tuberculosis* (Kleinnijenhuis et al., 2011; Schlesinger, 1996). Mice deficient in MyD88
280 lose resistance to *M. tuberculosis*, marked by reduced IL-12, TNF and Th1 cytokine
281 production and iNOS expression (Scanga et al., 2004). Similarly, *Card9*^{-/-} mice have
282 impaired host resistance to *M. tuberculosis* and higher bacterial burden (Dorhoi et al.,
283 2010), as well as mice deficient in NOD-2 (Divangahi et al., 2008). Hyper-virulent forms
284 *M. tuberculosis* have been demonstrated to augment TLR signalling to their advantage. It
285 was recently shown that the virulent Beijing (Bj) lineage of *M. tuberculosis* preferentially
286 signals through TLR-2 as opposed to TLR-4 that is seen in less virulent strains, leading to
287 the induction of a less protective cytokine profile (Carmona et al., 2013).

288 In fish, recognition of *M. marinum* PAMPs by PRRs can induce the nitrosative
289 defense mechanism in leukocytes, which is attenuated in *M. marinum* containing the RD-
290 1 virulence locus (Elks et al., 2014), or in *M. marinum* absent cell wall phthiocerol
291 dimycocoserate (PDIM) lipids (Cambier et al., 2014). These findings emphasize both
292 the importance of TLRs to initiate appropriate immune function, as well as evasion
293 techniques that *M. marinum* possess by disruption of these interactions. Impairment in
294 MyD88 of zebrafish can also accelerate granuloma formation (van der Vaart et al., 2012),
295 although this is likely also due to the loss of IL-1 signalling, which is also MyD88
296 dependant. Damaged host molecules have also been shown to be important to
297 antimycobacterial immunity in fish, where TLRs in zebrafish have been shown to
298 mediate autophagy by binding DNA damage-regulated autophagy modulator (DRAM1)
299 (Meijer and van der Vaart, 2014), demonstrating the importance of TLR signalling in

300 later stages of infection. The implication of NLR signalling has also been suggested in
301 expression studies of goldfish primary kidney leukocytes following stimulation with *M.*
302 *marinum* (Xie et al., 2013).

303

304 **Early regulation of cytokine production**

305 Early recognition of mycobacterial PAMPs by mammalian PRRs results in the
306 production of a number of cytokines, including tumour necrosis factor (TNF), interferon
307 (IFN)- γ , and IL-1 family cytokines (IL-1 α , IL-1 β , IL-18 and IL-33), IL-12, IL-17 and IL-
308 23. Orthologous cytokines of the fish have also been studied in acute mycobacterial
309 infections, although not extensively. Evaluation of cytokine gene expression following
310 BCG vaccination in Japanese medaka has shown early increases in IL-1 β , IL-6, IFN- γ
311 and TNF α , akin to mammalian observations. Similar responses have been observed in
312 goldfish and adult zebrafish (Berrington and Hawn, 2007; Reiling et al., 2008; Yang et
313 al., 2012a).

314 Among the cytokines participating in these responses, TNF has long been
315 recognized as critical for protection against mycobacterial infection. The importance
316 of TNF signaling was first revealed by blocking with anti-TNF receptor antibodies,
317 which increased bacillary load within the granuloma and expedited host death
318 (Bean et al., 1999; Flynn and Chan, 2001). Moreover, interference with TNF
319 signaling during latent infection resulted in reactivation, suggesting an important
320 role in maintaining a latency programme and fending off active disease (Botha and
321 Ryffel, 2003; Chakravarty et al., 2008; Mohanty et al., 2015). Impaired TNF function
322 in mycobacterial infection reduces iNOS and increases IL-10 production, while IFN- γ
323 and IL-12 remain unchanged (Mohan et al., 2001). It has been suggested that TNF is
324 required for the generation and maintenance of granulomas (Bean et al., 1999;
325 Chakravarty et al., 2008), although this has been shown to not necessarily be the
326 case, where various infection models have demonstrated granuloma formation in
327 the absence of TNF (Flynn and Chan, 2001; Iliopoulos et al., 2006; Lin et al., 2010).

328 Experiments using goldfish and zebrafish have revealed the importance of a
329 balanced TNF response in the control of mycobacterial infection. Similar to
330 mammalian models, TNF induces a mycobacterial killing response by stimulating

331 effector RNS and ROS in macrophages (Grayfer et al., 2011; Roca and Ramakrishnan,
332 2013). TNF is induced in early infection events in zebrafish, leading to restriction of
333 the growth of *M. marinum* (Clay et al., 2007). Unsurprisingly, morpholino
334 knockdown of TNF receptor (TNFR) led to increased bacterial growth and
335 decreased containment (Clay et al., 2008), although hyper-expression of TNF is also
336 unfavorable to the host, enhancing inflammation and necrosis (Roca and
337 Ramakrishnan, 2013; Tobin et al., 2012). The temporal duality in outcome of TNF
338 signaling has been clearly described in the zebrafish system (Roca and
339 Ramakrishnan, 2013). Interestingly, chemical inhibition of necrosis in high TNF fish
340 have been shown to uncouple the positive and negative effects and is a possible
341 therapeutic approach for treatment of TB.

342

343 **PHAGOCYTOSIS ANTIMICROBIAL RESPONSES**

344 Internalization of mycobacterial bacilli by responding phagocytes is mediated by
345 mannose, complement, and scavenger receptors (Kleinnijenhuis et al., 2011). Following
346 internalization, mycobacteria are either neutralized by activated phagocytes (through the
347 respiratory burst, nitric oxide production, or phagolysosomal events), or bacteria may
348 persist within the phagocyte (Castaneda-Delgado et al., 2010; Fabri et al., 2011). Evasion
349 of host effector responses can result in latent infection or acute, active disease (Frieden et
350 al., 2003). Generation of an appropriate immune response during early events play a
351 critical role in determining the fate of infection, either through protective innate immunity
352 or adaptive responses (Frieden et al., 2003).

353 The cellular interactions between host leukocytes and *M. marinum* have been well
354 documented early during fish infection. In the zebrafish embryo model transparency
355 enables visualization of these interactions. Similar to mammalian models, resident fish
356 macrophages readily internalize *M. marinum* (Davis et al., 2002) and neutrophils rapidly
357 migrate to the site of infection and uptake the pathogen (Abadie et al., 2005; Clay et al.,
358 2007), although neutrophil phagocytosis of *M. marinum* is largely dependent on the site
359 of infection (Yang et al., 2012a).

360

361 **Phagosome maturation**

362 Pathogenic mycobacteria have evolved a number of evasion strategies to subvert
363 the hostile environment following professional phagocytic internalization. Pathogenic
364 *Mycobacterium* spp. are particularly adept at interfering with the maturation of the
365 phagosome, restricting acquisition of late endosomal or lysosomal characteristics
366 (Clemens and Horwitz, 1996; Sturgill-Koszycki et al., 1994). In mammals, a number of
367 mycobacterial factors have been identified that interfere with phagosomal maturation and
368 lysosomal fusion. The mycobacterial cell wall lipid phthiocerol dimycocerosates (PDIM)
369 contributes to host cell entry through receptor-dependant phagocytosis, and also impairs
370 phagosome maturation and acidification, compared to PDIM mutants (Astarie-Dequeker
371 et al., 2009; Pethe et al., 2004). Trehalose 6,6'-Dimycolate (TDM) and
372 lipoarabinomannan (LAM) have also been shown to play an important role in arresting of
373 normal phagosome processing (Axelrod et al., 2008; Welin et al., 2008). More recent
374 findings suggest pathogenic mycobacteria can escape the phagosome by translocating to
375 the cytosol, although this may only occur at later stages in infection at the level of the
376 granuloma (Bafica et al., 2005).

377 *M. marinum* infection of teleost models corroborate interference with phagosome
378 maturation findings described above. Circumvention of the phagosome and lysosome has
379 been demonstrated by *M. marinum* in trout and carp macrophages (Barker et al., 1997;
380 El-Etr et al., 2001), and the pathogen has also been shown to localize in non-acidified
381 phagosomes (El-Etr et al., 2001). Most recently, it has also been shown that *M. marinum*
382 are able to survive and grow within the phagolysosomal compartment, albeit at slower
383 growth rates, through action of the virulence determinant MarP (Levitte et al., 2016).

384

385 **Respiratory burst**

386 The fate of internalized particles depends heavily on the activation state of the
387 phagocyte. Increased risk of mycobacterial diseases is observed in humans with chronic
388 granulomatous disease, where defective NADPH oxidase is incapable of producing ROS
389 in phagocytes (Deffert et al., 2014). However, controversy over the role of ROS exists, as
390 it has been shown that mice deficient in NOX2 are relatively resistant to mycobacterial
391 infection (Adams et al., 1997; Cooper et al., 2000; Jung et al., 2002). *M. tuberculosis*
392 possesses a number of resistance mechanisms for neutralizing reactive oxygen products,

393 including *katG* catalase-peroxidase, an enzyme that neutralizes H₂O₂ into H₂O and O₂. *M.*
394 *tuberculosis katG* mutants (*MtbΔkatG*) cannot grow in wildtype and iNOS^{-/-} macrophages,
395 but grow inside NOX2 deficient mice (gp91phox^{-/-}) (Ng et al., 2004). Additionally, *M.*
396 *tuberculosis* possesses two superoxide dismutase genes, *sodA* and *sodC*, which catalyze
397 the conversion of superoxide anions to hydrogen peroxide and water. These enzymes are
398 critical for virulence in several other pathogens, including *Helicobacter pylori*,
399 *Salmonella typhimurium* and *Yersinia enterocolitica* (Ehrt and Schnappinger, 2009).
400 Deletion of *sodC* has led to increased susceptibility to superoxide and killing in IFN-γ-
401 activated, but not TLR-activated murine macrophages, which may correspond to
402 functional importance at later stages of infection (Piddington et al., 2001). *SodA* seems to
403 play a complementary role to *SodC*, and it has been shown to protect against ROS in
404 TLR-activated macrophages during infection (Dussurget et al., 2001), where *SodA*
405 mutants were attenuated in mouse infection models (Edwards et al., 2001).

406 Fish possess orthologous NADPH oxidase machinery and are similarly capable in
407 producing toxic reactive oxygen intermediates from both TLR and cytokine activation
408 (Grayfer et al., 2014). *In vitro* and *ex vivo* studies of *M. marinum* in the goldfish have
409 shown attenuation of IFN-γ and TNF-α activated ROS production by kidney
410 macrophages (Grayfer et al., 2011; Hodgkinson et al., 2012). In the zebrafish model, ROS
411 in macrophages has been shown to kill intracellular *M. marinum*, although excessive
412 activation of infected macrophages by TNF led to induction of programmed necrosis
413 (necroptosis) resulting in the release of bacteria into the extracellular milieu, which is
414 more growth permissive (Roca and Ramakrishnan, 2013). More recently, *M. marinum*
415 cell wall component phosphoribosyltransferase has been shown to enhance bacterial
416 survival by inhibition of oxidative stress and autophagy pathways (Mohanty et al., 2015).
417 These findings highlight the importance of fine-tuning the regulation of ROS, where both
418 inhibition and excessive activation enhances bacterial growth and disease pathology.

419

420 **Nitric oxide antimicrobial response**

421 In addition to respiratory burst, activated macrophages express inducible nitric
422 oxide synthase (iNOS/NOS2), enzymes that catalyzes the conversion of L-arginine to L-
423 citrulline, resulting in the production of a potent antimicrobial compound, NO

424 (MacMicking et al., 1997). iNOS has become the hallmark of classically activated
425 macrophages, which are effector cells with a “kill” phenotype, as opposed to the
426 homeostatic “repair phenotype of alternatively activated macrophages (Gordon, 2003).
427 Stimulation of macrophages with PAMPs (e.g. LPS) or inflammatory cytokines (e.g.
428 IFN- γ) leads to activation of iNOS and production of large amounts of nitrate (NO₂⁻) and
429 nitrite (NO₃⁻), known as reactive nitrogen species (RNS) (Stuehr and Marletta, 1987).
430 Parallel production of superoxide and NO can also result in the formation of peroxynitrite
431 (ONOO⁻), a potent antiparasitic/antimicrobial agent (Henard and Vazquez-Torres, 2011).
432 Like ROS, RNS can modify DNA, proteins and lipids, resulting in antimicrobial function,
433 but can also damage host cells (Yang et al., 2009). Activation of iNOS is essential for the
434 destruction of intracellular pathogens, including mycobacteria (Adams et al., 1991; Schon
435 et al., 2004). Indeed, iNOS knockout studies have demonstrated uncontrolled bacterial
436 replication, dissemination, tissue destruction and mortality (MacMicking et al., 1997).

437 Members of the *M. tuberculosis* complex possess a number of virulence factors to
438 combat host RNS. Exposure to NO can trigger a transition to dormancy, leading to
439 persistence of infection (Voskuil et al., 2003; Wayne and Sohaskey, 2001). The sensing
440 of NO is accomplished through a three-component dormancy survival regulator
441 (DosR/S/T), which shifts the bacteria from aerobic to anaerobic metabolism to enter
442 dormancy (Green et al., 2014). Other virulence factors involved in denitrification include
443 TpX, a thiol peroxidase that reduces peroxynitrite (Jaeger et al., 2004), AhpC, a catalase
444 peroxidase (Sherman et al., 1999), PknE, a serine/threonine kinase E, an inhibitor of NO-
445 mediated apoptosis (Jayakumar et al., 2008). Forrellad et al. recently published a
446 comprehensive review on mycobacterial virulence factors that combat oxidative and
447 nitrosative stress (Forrellad et al., 2013).

448 Infections of *M. marinum* in fish have yielded corroborative insights into the role
449 of iNOS in mycobacterial immunity. In zebrafish, TLR (MyD88 dependent) recognition
450 of *M. marinum* resulted in NO production, although bacteria containing the RD1 locus,
451 were capable of attenuating the response (Elks et al., 2014). Interestingly, *M. marinum*
452 has recently been shown to preferentially recruit permissive macrophage phenotypes
453 during early infection, which do not produce nitric oxide upon internalization (Cambier et
454 al., 2014). This evasive “screening” of macrophages is accomplished using cell-surface-

455 associated phthiocerol dimycocerosate (PDIM) lipids which mask underlying PAMPs and
456 recruit permissive macrophages through a host chemokine receptor 2 (CCR2)-mediated
457 pathway (Cambier et al., 2014). In PDIM deficient *M. marinum*, TLRs stimulation leads
458 to recruitment of macrophages with microbicidal potential through nitrosative
459 mechanisms. Further reports using the zebrafish model demonstrated that the
460 enhancement of iNOS reduced bacterial burden, while impaired iNOS increases host
461 susceptibility, and the Dos dormancy survival regulon is also seemingly conserved (Chen
462 et al., 2016b). *In vitro* and *ex vivo* dampening of cytokine-induced nitric oxide production
463 has also been observed in goldfish macrophages, suggesting conserved mechanisms for
464 attenuating iNOS function in teleosts (Grayfer et al., 2011; Hodgkinson et al., 2012).

465

466 **Tryptophan degradation**

467 The IFN- γ -elicited expression of macrophage indoleamine 2,3-dioxygenase (IDO)
468 is another marker of classical macrophage polarization, which oxidizes L-tryptophan to
469 N-formylkynurenine (Taylor and Feng, 1991). Expression of IDO can be induced by
470 either IFN or TLR pathways, and is generally accepted to deprive supply of tryptophan to
471 pathogens, limiting growth and persistence (Green et al., 2014; Wayne and Sohaskey,
472 2001); (Wang et al., 2014). The catabolism of L-tryptophan also results in production of
473 metabolites known as kynurenines, which promote a broad spectrum of downstream
474 effects, including immunotolerance and suppression of T cell proliferation (Grohmann
475 and Bronte, 2010).

476 Despite the presence of the IDO-mediated approach to pathogen control,
477 pathogenic mycobacteria are capable of *de novo* L-tryptophan biosynthesis, rendering a
478 deprivation strategy by IDO ineffective. In fact, increased IDO expression correlates with
479 severity of pathology in *M. tuberculosis* infected individuals (Plain et al., 2011). *M.*
480 *tuberculosis* actively promotes host IDO production and suppression of IDO reduces
481 bacterial burden, pathology, and clinical signs of TB disease, leading to increased host
482 survival (Gautam et al., 2018). Downstream effects of kynurenine metabolite production
483 are also likely to interfere with T cell activation, a critical component of anti-
484 mycobacterial immunity. Thus, interference of IDO has been proposed as a potential

485 therapeutic target, in addition to the L-tryptophan biosynthesis machinery in
486 mycobacteria, anthranilate synthase (TrpE) (Warner, 2015; Zhang et al., 2013).

487 Fish IDO orthologues (proto-IDOs) appear to have less efficient tryptophan
488 degradative capacities as compared to the mammalian IDOs, suggesting the possible
489 presence of alternative fish IDO substrates that are yet to be identified (Yuasa et al.,
490 2007). To date, only one expression analysis of proto-IDO orthologues has been
491 presented in the context of mycobacterial infection. Goldfish macrophages infected with
492 *M. marinum* up-regulated proto-IDO gene expression and exposure of macrophages to
493 live *M. marinum in vitro* and induced substantially greater proto-IDO mRNA levels than
494 the heat-killed bacteria, suggesting a possibly similar tryptophan metabolism strategy
495 seen in mammalian hosts pathogen infection models (Grayfer et al., 2011). Similarly, our
496 group has observed large increases in IDO expression levels in *M. marinum* infected
497 spleen and kidney tissue.

498

499 **MODULATION OF MACROPHAGE SURVIVAL**

500 **Macrophage apoptosis**

501 Regulated cell death by infected cells is an important mechanism to contain
502 pathogen replication and spread. The importance of apoptosis to an effective immune
503 response is underlined by the various pathogenic virulence factors that inhibit the process
504 (Best, 2008). Apoptosis in *M. tuberculosis* infected macrophages is generally regarded as
505 a host protective response, where intact bacteria encased in plasma membrane are
506 internalized by phagocytes in a process called efferocytosis (Martin et al., 2012).
507 Sequestration of mycobacteria inside of the apoptotic body is thought to disrupt the
508 interference of phagolysosomal fusion following phagocytosis, thereby delivering the
509 bacilli to lysosomal components and facilitating degradation (Kagina et al., 2010).
510 Apoptosis was first recognized as an important line of defense against mycobacteria
511 when attenuated *M. tuberculosis* strains such as *M. tuberculosis* H37Ra exhibited reduced
512 viability and increased apoptotic turnover (Keane et al., 2000), whereas virulent *M.*
513 *tuberculosis* strains induced less apoptosis and persisted intracellularly (Kelly et al.,
514 2008). Pro-apoptotic mutants have led to the discovery of virulence factors that impair
515 apoptotic function, including the *secA2* gene, a secretion system that secretes

516 mycobacterial superoxide dismutase, a strong superoxide scavenger (Hinchey et al.,
517 2007). Contradictory reports suggest apoptosis can also promote mycobacterial spread
518 (Early et al., 2011) although this is likely due to contrasting stages of infection,
519 species/strain differences and immunological context.

520 Fish models have also demonstrated the importance of apoptosis in the control of
521 mycobacterial infection. Recently, PDIM deficient *M. marinum* was shown to increase
522 the level of apoptosis in early infection compare to wild type bacteria in the zebrafish
523 embryo model, although these roles were reversed in the granuloma (Huang et al., 2016).
524 The increased apoptosis in the granuloma leading to the expansion of infected
525 macrophages has previously been demonstrated in zebrafish larval granulomas possessing
526 the RD1 virulence locus (Davis and Ramakrishnan, 2009), reiterating the immunological
527 context of these processes as paramount.

528

529 **Macrophage necrosis**

530 Recent insights into death by necrosis has added a nuanced view of what was
531 originally considered ‘un-controlled cell death’. This original definition holds as partially
532 true, where unfavorable chemical physical conditions results in unregulated cell death.
533 However, a number of controlled states of necrosis have been defined (Feoktistova and
534 Leverkus, 2014). The means of mycobacterial control by necrotic cell death is
535 complicated. The well-acknowledged role of TNF for host defense has also been shown
536 to exacerbate disease outcomes through programmed necrosis, by excessive ROS
537 production (Roca and Ramakrishnan, 2013; Tobin et al., 2012; Tobin et al., 2010).
538 Eicosanoids have been shown to regulate the axis of cell death, where induction of
539 lipoxin (LXA4) and inhibition of prostaglandin (PGE2) by virulent strains of *M.*
540 *tuberculosis* led to programmed necrosis and mycobacterial spread. Mice deficient in
541 PGE2 are more susceptible to mycobacterial infection due to enhanced necrosis, while
542 LXA4 mutations enhance apoptotic response, leading to less susceptibility (Divangahi et
543 al., 2010).

544 Comparative models have been critical in advancing our understanding of necrotic
545 cell death with regards to mycobacterial disease, and caseating necrosis has been
546 observed in zebrafish, goldfish and tree frog granulomas, commensurate with heightened

547 pathology. The discovery of polymorphisms in *Itah* (leukotriene A4 hydrolase) was
548 originally done in the zebrafish, and was later demonstrated in susceptible human
549 populations (Herb et al., 2008; Tobin et al., 2010). Host mechanisms of control
550 influencing the development of a necrotic core in the granuloma have been elegantly
551 demonstrated in the zebrafish model. Restriction of macrophage recruitment to the
552 granuloma resulted in necrosis of core macrophages, and was highlighted as a tipping
553 point where fresh macrophage recruitment was exceeded by the demand within the
554 granuloma (Pagan and Ramakrishnan, 2015). Virulence products of the ESX-5 secretion
555 system have also been identified as influencers the necrotic/apoptotic balance in fish,
556 where knockouts shift drive a hyper-virulent necrotic response in the center of the
557 granuloma, though the mechanism underpinning this observation is unclear
558 (Weerdenburg Eveline et al., 2012).

559

560 **NEUTROPHILS**

561 The roles of neutrophils during mycobacterial infection remain controversial,
562 although neutrophils are infected by mycobacteria, and are the predominant infected cell
563 type during active tuberculosis (Eum et al., 2010; Francis et al., 2014). Numerous reports
564 suggest a negative role for neutrophils in tuberculosis, where respiratory failure and death
565 are associated with elevated blood neutrophil levels (Barnes et al., 1988; Lowe et al.,
566 2013). Further reports have shown neutrophils to facilitate delivery of mycobacteria to
567 dendritic cells, thereby aiding in the subsequent activation of CD4⁺ T cells (Blomgran et
568 al., 2012). Similar to what is seen in macrophages, apoptosis of neutrophils is inhibited
569 by pathogenic mycobacteria, leading to the delayed priming of CD4⁺ T cells,
570 concomitantly resulting in a higher bacterial load per cell (Blomgran et al., 2012). The
571 contribution to pathology and/or host protection is likely due to host/pathogen genetic
572 factors, as well as the stage of disease and immune context. Indeed, early events that
573 accompany infiltration of neutrophils to the infection site influence activation states
574 differently than at later stages in the granuloma. Early protective effects of neutrophils has
575 been observed, while depletion of neutrophils at later stages of infection has been shown
576 to reduce the bacterial load (Zhang et al., 2009). Therefore, it may be possible that early
577 protective responses and promotion of T cell activation by neutrophils renders later

578 immune contribution unnecessary, and disruption of this tightly controlled process may
579 lead to neutrophil pathology at later disease stages. Indeed, it has been suggested that
580 neutrophilia during active disease is an indication of failed Th1 immunity (Nandi and
581 Behar, 2011).

582 In fish models, recent interest in neutrophils in *M. marinum* infection has helped
583 to underline their importance in protection. Initially, it was thought that macrophages but
584 not neutrophils internalize *M. marinum*, as this was observed following injection of
585 bacilli into the bloodstream or hindbrain of zebrafish embryos (Yang et al., 2012a).
586 Subsequent reports showed chemotaxis and internalization of *M. marinum* by primary
587 goldfish neutrophils, as well as changes to pro-inflammatory status and killing capacity of
588 these adult teleost neutrophil populations (Hodgkinson et al., 2015). The survival of
589 intracellular mycobacteria was significantly reduced in activated neutrophils. Similarly,
590 in zebrafish internalization of *M. marinum* by neutrophils in subcutaneous infection
591 studies suggested that site specificity of infection exists, and is more likely to reflect the
592 natural role for neutrophils in early infection (Hosseini et al., 2016). Further, a recent
593 report in zebrafish using confocal laser scanning methods illustrated that neutrophils may
594 also contribute more to the dissemination of bacteria than macrophages, due to their high
595 mobility post infection (Hosseini et al., 2016). Clarification of the role of neutrophils in
596 early infection has been greatly aided in the zebrafish model, where death by bacteremia
597 is associated with neutropenia, further suggesting a protective response by neutrophils
598 (Belon et al., 2014). This is corroborated in transgenic zebrafish expressing truncated
599 chemokine receptor Cxcr4 leading to retention of neutrophils in hematopoietic
600 compartments and an increase in the bacterial burden (Yang et al., 2012a). Interestingly,
601 enhancing nitric oxide production of neutrophils prior to infection by manipulation of
602 hypoxia-inducible factor (Hif- α) signaling mediated a protective response, **an effect**
603 **dependent on Il-1 β production** (Elks et al., 2013; **Ogrysko et al., 2018**). At the granuloma,
604 neutrophils have been shown to internalize apoptotic bodies of macrophages, scavenging
605 and killing internalized bacilli via oxidative mechanisms (Hosseini et al., 2016; Yang et
606 al., 2012a). In this manner, neutrophils play an important protective role at the later
607 stages of infection in fish models.

608

609 CD4+ T CELLS

610 Th1

611 Adaptive immunity is first detectable between 3-8 weeks post mycobacterial
612 infection (Jasenosky Luke et al., 2015), which is widely accepted as being delayed
613 compared to other bacterial infections (Urdahl et al., 2011; Winslow et al., 2008). This
614 adaptive response is highly dependent on T helper cells, although the evidence is highly
615 correlative, as suggested by the increased susceptibility to TB in HIV coinfection
616 (Cooper, 2009). Following initial infection and internalization events, antigen presenting
617 cells, predominantly dendritic cells, traffic to a nearby lymph node and stimulate CD4+ T
618 cell expansion, although inhibition of MHC class II peptide presentation by *M.*
619 *tuberculosis* has been observed as a proposed evasion mechanism (Yang et al., 2012a).
620 The delay in T cell expansion may in part be due to delayed migration of dendritic cells
621 that may internalize apoptotic bodies of infected macrophages or neutrophils (Blomgran
622 and Ernst, 2011; Divangahi et al., 2010). However, once migrated, infected dendritic cells
623 are capable of releasing intact bacterial antigens that are taken up and presented by the
624 uninfected dendritic cells, optimizing T cell priming (Srivastava and Ernst, 2014).
625 Following DC migration and T cell activation, further delays in effector function has
626 been observed. Interestingly, even fully differentiated pathogen-specific Th1 cells that are
627 transferred to a naïve host prior to infection do not provide protection against *M.*
628 *tuberculosis* for 7 days post infection (Gallegos et al., 2008), demonstrating that
629 following T cell activation there is inhibition of movement and downstream effects.

630 Antigen-driven differentiation of T cells results in the capacity of CD4+ (and to a
631 lesser extend CD8+) to produce essential Th1 cytokines, particularly IFN- γ , which is well
632 established in protection against mycobacterial pathogens (Rossouw et al., 2003). These
633 cytokines are critical for activation of the antimycobacterial function of macrophages,
634 including phagosome maturation, reactive nitrogen intermediates and antigen
635 presentation (described above) (Flynn et al., 2011; Weiss and Schaible, 2015). Indeed,
636 cessation of bacterial growth correlates strongly to the arrival of CD4+ T cells to the
637 infection site or granuloma, although the mechanisms have yet to be fully defined.
638 Evidence for the protective capacity of multifunctional CD4+ T cells, subtypes that
639 produce IL-2, IFN- γ and TNF α , suggest the balanced combination of cytokine levels to

640 be an important factor (Darrah et al., 2007). Development of multifunctional Th cells
641 seems to depend heavily on antigen presentation of dendritic cells, as well as proper
642 cytokine stimulation of a well-orchestrated innate immune response, but maintenance of
643 the response is not fully elucidated.

644 The adaptive components of the immune response to mycobacterial infection is
645 not well established in fish. This is partially owing to the relative lack of reagents in
646 teleost systems, although T cells (TcR and CD4-related genes), as well as B cells have
647 been identified in bony fish (Castro et al., 2013a; Castro et al., 2013b). Recently, antigen
648 induced cytokine production of CD4+ T cells was observed in adult zebrafish, where *M.*
649 *marinum* infected fish showed a collection of Th cells surrounding the granuloma, similar
650 to that of mammalian infection models (Yoon et al., 2015). Importance of T cells for the
651 control of mycobacterial infection was corroborated in fish, where depletion of CD4+ T
652 cells corresponded to granuloma disruption and dissemination of *M. marinum*
653 (Myllymaki et al., 2018). However, most of the research in the zebrafish has focused on
654 the embryonic system which predates development of lymphocytes. Correlative
655 importance of Th cells in mycobacterial control has been assessed with regards to IFN- γ
656 expression. Increases in IFN- γ mRNA expression has been observed in adult goldfish and
657 zebrafish *in vivo* (Hodgkinson et al., 2012; Oksanen et al., 2013; Yoon et al., 2015) and in
658 goldfish primary cultures (Grayfer et al., 2011). IFN- γ -primed macrophage effector
659 function was also shown to be attenuated by *M. marinum*, suggesting effector evasion
660 even with IFN- γ stimulation (Grayfer et al., 2011).

661

662 **Th2**

663 CD4+ T cells can functionally polarize to Th2 cells, which generally produce IL-
664 4, IL-5, IL-10, and IL-13, stimulating a strong antibody response and inhibiting
665 antimicrobial macrophage activation (Romagnani, 1999). Because Th1 responses are
666 generally regarded as host protective, Th2 responses, known to cross-regulate and inhibit
667 Th1, may be counterproductive in mycobacterial control. Relatively little research has
668 been conducted with regards to Th2 responses in mycobacterial infections, although
669 chronic helminth infection appears to decrease immunogenic response of BCG (Elias et
670 al., 2008) and impairs a productive Th1 response in concurrent *M. tuberculosis* infections

671 (Babu et al., 2009; Resende Co et al., 2007). Interestingly, IL-4R α ^{-/-} deficient mice
672 infected with a helminth, exhibited improved ability to combat mycobacterial infection,
673 suggesting that a possible mechanism of interference is the alternative activation of
674 macrophages, a functional state that naturally down-regulates iNOS function (Potian et
675 al., 2011).

676 Fish possess a Th2/M2 functional state in response to parasitic infection, which
677 has been exhibited by increases in arginase activity in macrophages (Joerink et al., 2006).
678 Fish also have Th2-type cytokines capable of a homologous regulatory and anti-
679 inflammatory role, as has been demonstrated in goldfish macrophages exposed to
680 recombinant forms of IL-4 (Hodgkinson et al., 2017). Zebrafish Th2-like cells have been
681 characterized in response to *M. marinum* infections (Yoon et al., 2015), and interestingly,
682 adequate Th2 gene expression levels are necessary for well-controlled latency
683 (Hammaran et al., 2014). It is likely the case that the timing and regulation of Th2
684 response is important in mycobacterial infection as well as containment in fish as well as
685 mammals.

686

687 **Tregs**

688 T regulatory cells (Tregs), characterized as CD4⁺ Foxp3⁺, are critical in the
689 regulation of immune responses to self-antigens and in promoting homeostasis. Tregs are
690 generally immunosuppressive through a number of mechanisms, including cytokine
691 production (TGF- β , IL-10, IL-35), induction of effector cell apoptosis, and increasing
692 IDO expression (Collison et al., 2007; Gondek et al., 2005; Read et al., 2000). Regulatory
693 T cells have been shown to accumulate at the lymph node and granuloma at a similar rate
694 of effector T cells during *M. tuberculosis* infection in mice (Scott-Browne et al., 2007).
695 Accumulation of Tregs has also been shown to prevent eradication of *M. tuberculosis* by
696 suppressing the Th1 response in an IL-10 independent manner, and where depletion of
697 Tregs also resulted in reduced bacterial load (Kursar et al., 2007). Despite the likelihood
698 of an impairment of an effective anti-mycobacterial response, it is still relatively unclear
699 the role of Tregs in different stages of infection, where they likely aid in minimizing
700 pathology by controlling inflammation.

701 Treg cell markers Foxp3 and Gata3 are present in teleost genomes and Tregs have
702 been identified as a functionally conserved cell type in puffer fish (Wen et al., 2011), sea
703 bass (Nunez Ortiz et al., 2014) and zebrafish (Dee et al., 2016; Hui et al., 2017; Kasheta
704 et al., 2017). A few studies of the contribution of Tregs cells to the immune response to
705 *M. marinum* have been undertaken in fish. In adult zebrafish, reactivation of latent *M.*
706 *marinum* infections was correlated with increased *foxp3* transcription levels, suggesting a
707 role for Tregs in this process (Hammaran et al., 2014). Further research is required in
708 both fish and mammalian model systems to determine the relative contribution of Tregs
709 to host protection/disease pathology during the course mycobacterial infection.

710

711 **Th17 cells**

712 T helper (Th) 17 may play a role in mycobacterial protection, as they are known
713 to have significant pro-inflammatory effects on intracellular pathogens (Cooper, 2009). In
714 TB, Th 17 cells have been shown to accumulate at the granuloma, but seem to be
715 counteracted by IFN- γ producing CD4⁺ T cells. This inhibition of IL-17 was shown to
716 limit the neutrophilic accumulation and survival, which may decrease inflammation and
717 improve the infection outcome (Nandi and Behar, 2011). Contradictory reports have also
718 shown the IL-17 response is dispensable in with sufficient IL-12p70 production (Khader
719 et al., 2005). Still, partial protection has been reported following transfer of antigen-
720 specific Th 17 cells in to naïve hosts (Gallegos et al., 2011). The variety of roles for IL-
721 17 and Th 17 cells is likely due to genetic variability in host and pathogen models, and
722 more work is necessary to understand the role of Th 17 cells in mycobacterial host
723 defense. At present, little has been established regarding IL-17 participation in *M.*
724 *marinum* infection, although in zebrafish this has been inversely correlated with increases
725 in IL-17 expression levels (Ojanen et al., 2015).

726

727 **CD8⁺ T CELLS**

728 Although comparatively less studied, CD8⁺ T cells have been described during
729 TB infection. Antigen specific CD8⁺ T cells are found at the site of active disease but
730 seem to possess less cytotoxic activity compared with latently infected individuals
731 (Andersson et al., 2007). Decreases in IFN- γ ⁺ TNF⁺ IL-2⁺ trifunctional CD8⁺ T cells has

732 been observed in active disease states as well as cellular dysfunction in individuals with
733 high bacterial load (Day et al., 2011), marked by a higher proportion of pro-apoptotic
734 markers and diminished proliferative capacity (Day et al., 2014). It has been suggested
735 that during active disease, *M. tuberculosis*-specific CD8⁺ T cells are arrested in an
736 intermediate point in differentiation with a reduced capacity for cytotoxicity and
737 proliferation (Jasenosky Luke et al., 2015). Inhibition of T cell function is exacerbated in
738 TB patients taking anti-TNF therapy for auto-immune disorders (Bruns et al., 2009). This
739 may mean that impaired upstream activation events, i.e. macrophage of Th1, lead to
740 arrested CD8⁺ function.

741 In fish, T cells express typical markers, including CD8, and have homologous
742 cytolytic function (Castro et al., 2013). CD8⁺ activation has been implicated in fish
743 immunity towards *Edwardsiella tarda* (Rowe et al., 2014), although to date, there is no
744 contribution from fish models on the research of CD8⁺ T cells during mycobacterial
745 infection.

746

747 **B CELLS**

748 B cells and antibody production are vital for a protective response and vaccination
749 to numerous infectious agents, although their contribution to mycobacterial protection is
750 not well understood. It was originally conceived that B cells do not contribute
751 meaningfully toward protection due to the intracellular nature of *M. tuberculosis*
752 (Kumararatne, 1997), although they likely play a role beyond what was previously
753 thought (Maglione Paul and Chan, 2009). B cells have been observed at the granuloma
754 where they may contribute to host defense (Phuah et al., 2012) and they have been shown
755 to influence inflammatory progression and bacterial containment (Maglione et al., 2007).

756 Most recently, antibodies have been implicated in a protective role during mycobacterial
757 infection via changes to their Fc functional properties (Lu et al., 2016). Individuals with
758 latent tuberculosis infection displayed functional enhancements including
759 phagolysosomal maturation, inflammasome activation, and macrophage killing of
760 intracellular *Mycobacterium tuberculosis*, when compared to individuals with active
761 tuberculosis disease (Lu et al., 2016).

762 Fish and mammalian B cells share many similarities, including the generation of
763 hyper-specific antibody repertoires by somatic gene rearrangement, and heavy chain
764 isotypes IgM and IgD. However, fish possess a unique antibody isotype profile, IgT/IgZ,
765 and lack IgG/IgE, although the exact isotype picture continues to evolve (Bengtén and
766 Wilson, 2015). Antibody production following infection with *M. marinum* has been
767 observed, although a definitive link to host protection is yet to be established (Cui et al.,
768 2010; Pasnik et al., 2003).

769

770 **IFN- γ**

771 It is well established that IFN- γ is essential for protective function towards
772 intracellular pathogens, including mycobacteria (Bach et al., 1997). CD4⁺ Th cells are
773 the predominant source of IFN- γ during mycobacterial infection. CD8⁺ T may also
774 produce IFN- γ , although they cannot compensate for a lack of CD4⁺ cells (Flynn and
775 Chan, 2001). Transient sources of IFN- γ from NK cells, NK T cells and $\gamma\delta$ T cells has
776 also been observed and is thought to tide over the protective response over until adaptive
777 sources take over, and also seem to be more prominent during infection with hyper
778 virulent *M. tuberculosis* infection (Cooper Andrea and Khader Shabaana, 2008). As
779 previously mentioned, antimicrobial mechanisms of the macrophage are critically
780 important in eradicating intracellular mycobacteria. IFN- γ is largely responsible for this
781 activation following expansion of antigen specific T cells. IFN- γ exerts numerous
782 downstream effects through a suite of transcriptional programs (Boehm et al., 1997),
783 activation of reactive oxygen production and iNOS transcription (MacMicking et al.,
784 1997), autophagy, endosome maturation (Russell et al., 2010), and production of
785 antimicrobial peptides (Fabri et al., 2011). Mice deficient in IFN- γ are unable to control
786 low dose infections of *M. tuberculosis*, where they fail to produce reactive intermediates
787 and bacteria replicate unabated (Cooper et al., 1993; Flynn et al., 1993). Similarly,
788 mutations in cognate receptor IFN- γ R1 has been implicated in fatal BCG infection
789 (Jouanguy et al., 1997). Despite the role in controlling infection, IFN- γ levels are
790 correlated with the severity of disease, where excessive levels of IFN- γ are seen in

791 patients with severe TB (Verbon et al., 1999), and these levels are reduced following
792 productive therapy (Tsao et al., 2002).

793 Not surprisingly, interferon signalling is similarly necessary in host protection of
794 fish towards *M. marinum*. Expression analysis confirms increases in interferon expression
795 levels following *M. marinum* infection in goldfish immune tissues (Hodgkinson et al.,
796 2012) and primary cultures (Grayfer et al., 2011). Interestingly, *M. marinum* impaired the
797 IFN- γ primed respiratory burst and nitric oxide response in cultured leukocytes (Grayfer
798 et al., 2011). In adult zebrafish, IFN- γ levels have corresponded to a partially protective
799 BCG vaccination (Oksanen et al., 2013) as well as iNOS activation (Parikka et al., 2012).

800

801 **IL-10**

802 IL-10 is produced by a variety of immune cells, including macrophages,
803 neutrophils, B cells, DCs and T cells (Saraiva and O'Garra, 2010) and provides critical
804 regulatory feedback of inflammation to prevent immunopathology (Cooper, 2009).
805 Similar to IFN or TNF, IL-10 can act as a double-edged sword during infection, where
806 precise control of IL-10 is imperative. Overproduction during mycobacterial infection has
807 been shown to contribute to chronic infection, while excessive inflammation and
808 pathology occurs with insufficient production (Saraiva and O'Garra, 2010). Mice
809 deficient in IL-10 exhibited enhanced protection to mycobacterial infection (Redford et
810 al., 2010; Roach et al., 2001) and the blocking of IL-10R signalling using antibodies has
811 resulted in decreased bacterial loads, enhanced T cell proliferation and IFN- γ production,
812 and host survival (Beamer et al., 2008). Interference of immune activation by IL-10 is
813 through a variety of mechanisms, including antigen presentation, limited development of
814 a Th1 response (and subsequent IFN- γ production), leading to inhibition of TNF, and
815 prevention of iNOS expression (Fiorentino et al., 1991; Moore et al., 2001). Accordingly,
816 mycobacterial pathogens have been shown to dampen host defence by modulating the IL-
817 10 response. Increased IL-10 production was shown to arrest phagosome maturation in
818 *M. tuberculosis* infected macrophages, while blocking IL-10 antibodies reversed this
819 effect (O'Leary et al., 2011). The relative pathogenicity of mycobacterial strains also
820 seems to correlate with IL-10 production, where hypervirulent strains of TB (HN878),
821 characterized by the presence of a phenolic glycolipid, have been shown to induce an

822 early IL-10 and arginase-1 expression via CD4+CD25+FoxP3+CD223+ regulatory T-
823 cells. Coinfection with complementary strains demonstrate a virulence mechanism
824 utilized by *M. tuberculosis* HN878 to exploit host immune systems through induction of
825 IL-10, which is presumed to be an immune evasion strategy (Reed et al., 2004). Thus, the
826 data in humans and other mammalian models largely points to IL-10 impairing the ability
827 to eradicate mycobacteria infection when in excess. Studies in fish, however, have not
828 reached this same consensus. *M. marinum* induced expression of IL-10 has been observed
829 in goldfish primary kidney monocytes and macrophages (Grayfer et al., 2011), although
830 no apparent increases of IL-10 were observed in spleen or kidney tissues during
831 infections (Hodgkinson et al., 2012), and introduction of recombinant IL-10 did not alter
832 the viability of *M. marinum* within goldfish phagocytes (Hodgkinson et al., 2012). In
833 zebrafish, IL-10 mutants showed enhanced survival and enhanced interferon gamma
834 response following chronic *M. marinum* infection (Harjula et al., 2018).

835

836 **MMP9**

837 Metalloproteinase 9 (MMP9) has been isolated as a critically important
838 chemotactic factor for recruiting macrophages and monocytes to the granuloma (Taylor et
839 al., 2006), and is increased in mice and humans infected with *M. tuberculosis* (Price et al.,
840 2001; Taylor et al., 2006). Chemical inhibition of MMPs in mice leads to delayed and
841 smaller granuloma formation (Hernandez-Pando et al., 2000), while heightened levels are
842 correlated with severity of disease (Chang et al., 1996).

843 Important findings on the contribution of MMP9 to pathology has been generated
844 in the zebrafish and been shown to be modulated by an RD-1 factor, ESAT-6. It was
845 observed that infected cells at the granuloma are not responsible for MMP9 production,
846 but rather nearby adjacent epithelial cells (Volkman et al., 2010). The stimulation of
847 MMP9 by epithelial cells is thought to attract naïve macrophages and monocytes while
848 simultaneously allowing for the dampened antimicrobial response in phagocytes in the
849 granuloma (Ramakrishnan, 2013). Moreover, these findings in the zebrafish offers
850 insights as to why granulomas do not typically grow in skeletal muscle or cardiac tissue,
851 due to the a lack of neighboring epithelial cells, responsible for MMP9 production.

852

853 **LIPID MEDIATORS**

854 Balance of the eicosanoids prostaglandin (PGE₂) and lipoxin (LXA₄) plays a
855 major role in the outcome of mycobacterial infection. The balance of PGE₂ and LXA₄
856 govern whether macrophages undergo apoptosis or necrosis, which is an important
857 determinant in host protection during infection (Behar et al., 2010). Less virulent
858 mycobacterial infections, including the BCG vaccine, preferentially increase PGE₂,
859 leading to apoptosis in macrophages and ultimately bacterial containment (Divangahi et
860 al., 2010). Deficiencies of PGE₂ in mice resulted in increased bacterial loads and host
861 susceptibility (Behar et al., 2011; Chen et al., 2008). In fish, an *ltah4* mutant led to
862 increased LXA₄ production resulting in greater host susceptibility to *M. marinum*
863 infection (Tobin et al., 2010). Heterozygous polymorphisms in the human *LTA4H*
864 promoter were found to be associated with TB severity in Vietnamese patients,
865 suggesting this could serve as the basis for effective therapies against tuberculosis (Tobin
866 et al., 2012), although it should be noted that changes in disease outcomes were not
867 observed in a Russian cohort with the same polymorphisms (Curtis et al., 2011).

868

869 **GRANULOMAS**

870 The granuloma is an organized cellular aggregate that can form in the presence of
871 ineradicable infectious or non-infections stimuli (Kunkel et al., 1989). The most
872 prominent known cause of granulomas are those generated in response to pathogenic
873 mycobacterial infections, giving rise to the name “tuberculosis” due to the hallmark
874 pathology (Ramakrishnan, 2013). Macrophages, the most prominent cell type in
875 granulomas, can undergo a variety of transformations, including interdigitation with other
876 macrophages as epithelioid cells, fuse into multinucleated giant cells, or differentiate into
877 foam cells, which are rich in lipids, thought to be due to the interference of lipid
878 metabolism by internalized mycobacteria. Finally, they can create caseous centers
879 within the granuloma by necrotic cell death, mediated by hypoxia (Hunter, 2011;
880 Ramakrishnan, 2013). The inner accumulation of macrophages in these heterogeneous
881 forms, as well as infected neutrophils, are surrounded by lymphocytes and fibroblasts that
882 create a fibrotic encapsulation (Peters and Ernst, 2003). A wide range of chemokine,

883 cytokine and adhesion molecules orchestrate the formation of granulomas, as reviewed in
884 (Peters and Ernst, 2003).

885 The granuloma was historically viewed as a generally protective feature, whereby
886 the host could effectively encase material that it could not destroy. This was partly due to
887 autopsies revealing healed granulomas with no live bacteria, suggesting the granuloma
888 was effective at controlling infection (Cosma et al., 2003). This is consistent with more
889 recent identification of phagocyte mediated killing of mycobacteria in early tuberculous
890 granulomas (Yang et al., 2012). Further, multiple forms of deficiencies, such as IFN- γ ,
891 TNF, IL-12 or MyD88 prevent the development of an organized granuloma, which
892 corresponded to hyper-susceptibility (Khader et al., 2006; Mohan et al., 2001), although
893 these deficiencies affect a number of other critical effector functions, such as macrophage
894 antimicrobial capacity. Paradoxically, acute disease is also marked by the existence of
895 granulomas, suggesting that granulomas often fail at controlling bacterial proliferation,
896 resulting in the alternate view of the granuloma as an immune response that is attempting,
897 but failing, to control the infection (Ramakrishnan, 2013).

898 It was previously thought that generation of granulomas requires adaptive
899 immunity, coinciding with slower growth of mycobacteria (North and Jung, 2004),
900 however, granuloma formation in zebrafish embryos infected with *M. marinum* occurs in
901 the absence of adaptive immune components, which are not present developmentally
902 (Davis et al., 2002). Visualization studies in zebrafish revealed that nascent granulomas
903 continually accept infiltrating macrophages and monocytes, responding to a chemokinesis
904 gradient, into the structure until they are heavily infected (Davis et al., 2002; Davis and
905 Ramakrishnan, 2009). Macrophage reprogramming that parallel E-cadherin-dependent
906 mesenchymal-epithelial transitions contribute to organized granuloma formation (Cronan
907 et al., 2016). Foam-like cells have also been identified using the zebrafish-*M. marinum*
908 granuloma model, where transdifferentiation of macrophages appears driven by the
909 mycobacterial ESX1 pathogenicity locus (Johansen et al., 2018). Vascularization further
910 supports granuloma formation, driven in part through CXCR4 (Torraca et al., 2017),
911 angiopoietin-2 (Oehlers et al., 2017), and VEGF (Walton et al., 2018). Interestingly, the
912 influence of chemokine production has been isolated to the RD-1 locus, where RD-1
913 deficient *M. marinum* attract fewer monocytes and macrophages to the nascent

914 granuloma, and bacterial expansion is much slower by comparison. Further, the attraction
915 of macrophages and monocytes to the granuloma by virulent mycobacterial strains results
916 in fresh phagocytes internalizing dead cell components containing live bacteria, thereby
917 multiplying the number of host cells (Ramakrishnan, 2013). Therefore, RD-1 deficient
918 mycobacteria are capable of infecting and multiplying intracellularly, but do not expand
919 further, likely due to the impaired recruitment of myeloid cells to the granuloma. While
920 the kinetics of monocyte and macrophage recruitment with regards to RD-1 have not
921 been confirmed in mammalian models, it appears there may be conserved function in
922 mice (Egen et al., 2011), and RD-1 deficient mycobacterial infections in mice also
923 demonstrate poorly formed granuloma structures (Sherman et al., 2004; Swaim et al.,
924 2006).

925 Further characterization of granuloma function has been elucidated in the
926 zebrafish embryo system, implicating the role of granulomas in disseminating infection.
927 Until recently, granulomas were viewed as static structures where bacteria were
928 contained and controlled. Visualization in the zebrafish model demonstrate the ability of
929 infected macrophages to efflux and seed new granuloma sites, by entering the blood
930 stream or through tissue parenchyma (Davis and Ramakrishnan, 2009). The zebrafish *M.*
931 *marinum* model has identified that the vascularisation of granulomas both nourishes the
932 bacteria aiding granuloma growth, but also facilitates dissemination of bacteria from
933 primary granulomas (Oehlers et al., 2015). Moreover, the onset of granuloma formation
934 has been shown to accelerate the proliferation of virulent mycobacteria, and attenuated
935 versions of *M. tuberculosis* were incapable of initiating the assembly of granulomas,
936 impairing bacterial growth (Volkman et al., 2004). Together, these data suggest an
937 alternate role to the granuloma as host protective structures. Validation of embryonic
938 studies is necessary due to the vast physiological discrepancies of the models, and the
939 embryo model may not always be the best for elucidating host: pathogen interactions. For
940 example, *M. marinum* deficient in ESX-5 was slightly attenuated in zebrafish embryos,
941 but hyper-virulent in adult zebrafish (Weerdenburg Eveline et al., 2012).

942

943 **CLINICAL IMPLICATIONS OF TELEOST MODELS**

944 Many of the examples of teleost mycobacterial research discussed in this review,
945 provide relevant and novel insights into the cellular and pathophysiology of
946 mycobacterial disease. The advantages of these model coupled to the difficulties of
947 infecting mice with the human pathogen *M. tuberculosis*, may render teleost models
948 increasingly important as we look to answer clinically relevant questions in TB.

949 One such clinically relevant question is understanding how TB manifests into life
950 threatening conditions. Many of the teleost models described in this review, address the
951 general mechanisms of granuloma formation, but not specifically addressing the location
952 microenvironment of diseased tissue. Tuberculosis meningitis has high morbidity and
953 mortality in the developing world, however little is known about how pulmonary TB
954 spreads from the lung to the brain (Wolzak et al., 2012). A recent zebrafish model of TB
955 meningitis, using *M. marinum* in embryo and adult infection, showed that the bacilli are
956 able to cross the blood brain barrier, either via a Trojan-horse mechanism by carriage in
957 macrophages, or without the need of macrophage help in an ESX-1 dependent manner
958 (van Leeuwen et al., 2018; van Leeuwen et al., 2014). Furthermore, there has been a
959 recent report of using zebrafish as a model for ocular TB, a condition that can cause
960 vision loss in affected patients (Takaki et al., 2018). These new *in vivo* models show great
961 promise in adding to our understanding of the complex nature of TB disease and has the
962 potential to open up completely novel treatment avenues as more is understood.

963 A key question in the TB clinic is how to target antibacterial drugs to infected
964 macrophages, and more importantly, to the centre of granulomas where latent and
965 potentially drug resistant, bacilli lie. The possibility of using nanoparticle drug delivery
966 vectors that target macrophages has been explored in the zebrafish *M. marinum* model.
967 Liposomes, containing antimycobacterials such as Rifampicin, have been shown to be
968 efficiently phagocytosed by macrophages in the *in vivo* zebrafish embryo and are
969 effective against *M. marinum* infection (Fenaroli et al., 2014). Furthermore, more
970 recently, liposomes have been modified to more easily cross endothelial barriers,
971 allowing larger nanoparticles to be used that remain able to penetrate granulomas but can
972 deliver larger payloads of drugs. These findings were recapitulated in a murine model of
973 TB, identifying that the zebrafish is a useful model to study nanoparticle drug delivery in
974 mammalian systems (Fenaroli et al., 2018).

975 Finally, the quest to improve the ageing and relatively ineffective Bacillus
976 Calmette-Guérin (BCG) vaccine is a key clinical aim. This has been addressed in the
977 zebrafish by combining the BCG vaccination, (which is modestly protective in an adult
978 zebrafish *M. marinum* model), with a DNA vaccine containing Ag85B, ESAT6 and a
979 resuscitation-related gene RpfE. This combination of antigens boosted the protective
980 effect of the BCG vaccine (Oksanen et al., 2016). The BCG vaccine neither prevents *M.*
981 *tuberculosis* infection nor inhibits the reactivation of latent TB in humans, and so
982 alternatives are being actively sought. The zebrafish is a useful screening tool for this
983 search and some alternative candidate antigens have recently been identified showing
984 promise for future novel vaccines (Myllymaki et al., 2018; Myllymaki et al., 2017).

985 The increase in study of teleost mycobacterial models makes it seem only a matter
986 of time before novel treatment strategies discovered in fish enter clinical trials and the
987 clinic itself rather than being used simply to inform the clinical situation.

988

989 **SUMMARY**

990 Various immune molecules and mechanisms have been established as relevant for
991 host protection against mycobacteria while many others are either controversial or poorly
992 defined. Despite an extensive body of work delineating various facets of immune
993 mechanisms and host evasion mechanisms, *M. tuberculosis* remains a deadly pathogen
994 responsible for millions of deaths annually. Teleost models offer an expanding platform
995 for understanding of mycobacterial infections and those mechanisms that offer the
996 greatest potential to enhance host protection.

997

998 **ACKNOWLEDGEMENTS**

999 This work was supported by the Natural Sciences and Engineering Council of
1000 Canada (NSERC) through grants to DRB (RGPIN-2018-05768) and MB (RGPIN-2014-
1001 06395). PME was supported by a Sir Henry Dale Fellowship jointly funded by the
1002 Wellcome Trust and the Royal Society (grant number 105570/Z/14/Z). JWH was
1003 supported by an NSERC PGS-D doctoral scholarship.

1005 **REFERENCES**

- 1006 WHO | Global tuberculosis report 2017, WHO.
- 1007 Adams, K.N., Takaki, K., Connolly, L.E., Wiedenhoft, H., Winglee, K., Humbert, O.,
1008 Edelstein, P.H., Cosma, C.L., Ramakrishnan, L., 2011. Drug tolerance in replicating
1009 mycobacteria mediated by a macrophage-induced efflux mechanism. *Cell* 145, 39-53.
- 1010 Adams, L.B., Dinauer, M.C., Morgenstern, D.E., Krahenbuhl, J.L., 1997. Comparison of
1011 the roles of reactive oxygen and nitrogen intermediates in the host response to
1012 *Mycobacterium tuberculosis* using transgenic mice. *Tubercle and Lung Disease: The*
1013 *Official Journal of the International Union Against Tuberculosis and Lung Disease* 78,
1014 237-246.
- 1015 Adams, L.B., Franzblau, S.G., Vavrin, Z., Hibbs, J.B., Krahenbuhl, J.L., 1991. L-
1016 arginine-dependent macrophage effector functions inhibit metabolic activity of
1017 *Mycobacterium leprae*. *Journal of Immunology (Baltimore, Md.: 1950)* 147, 1642-1646.
- 1018 Andersson, J., Samarina, A., Fink, J., Rahman, S., Grundstrom, S., 2007. Impaired
1019 expression of perforin and granulysin in CD8+ T cells at the site of infection in human
1020 chronic pulmonary tuberculosis. *Infection and Immunity* 75, 5210-5222.
- 1021 Babu, S., Bhat, S.Q., Kumar, N.P., Jayantasri, S., Rukmani, S., Kumaran, P., Gopi, P.G.,
1022 Kolappan, C., Kumaraswami, V., Nutman, T.B., 2009. Human type 1 and 17 responses in
1023 latent tuberculosis are modulated by coincident filarial infection through cytotoxic T
1024 lymphocyte antigen-4 and programmed death-1. *The Journal of Infectious Diseases* 200,
1025 288-298.
- 1026 Bach, E.A., Aguet, M., Schreiber, R.D., 1997. The IFN gamma receptor: a paradigm for
1027 cytokine receptor signaling. *Annual Review of Immunology* 15, 563-591.
- 1028 Bafica, A., Scanga, C.A., Feng, C.G., Leifer, C., Cheever, A., Sher, A., 2005. TLR9
1029 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to
1030 *Mycobacterium tuberculosis*. *The Journal of Experimental Medicine* 202, 1715-1724.
- 1031 Barker, L.P., George, K.M., Falkow, S., Small, P.L., 1997. Differential trafficking of live
1032 and dead *Mycobacterium marinum* organisms in macrophages. *Infection and Immunity*
1033 65, 1497-1504.
- 1034 Barnes, P.F., Leedom, J.M., Chan, L.S., Wong, S.F., Shah, J., Vachon, L.A., Overturf,
1035 G.D., Modlin, R.L., 1988. Predictors of Short-Term Prognosis in Patients with
1036 Pulmonary Tuberculosis. *The Journal of Infectious Diseases* 158, 366-371.
- 1037 Basaraba, R.J., Hunter, R.L., 2017. Pathology of Tuberculosis: How the Pathology of
1038 Human Tuberculosis Informs and Directs Animal Models. *Microbiology Spectrum* 5.
- 1039 Beamer, G.L., Flaherty, D.K., Assogba, B.D., Stromberg, P., Gonzalez-Juarrero, M., de
1040 Waal Malefyt, R., Vesosky, B., Turner, J., 2008. Interleukin-10 Promotes *Mycobacterium*
1041 *tuberculosis* Disease Progression in CBA/J Mice. *Journal of immunology (Baltimore,*
1042 *Md. : 1950)* 181, 5545-5550.
- 1043 Bean, A.G., Roach, D.R., Briscoe, H., France, M.P., Korner, H., Sedgwick, J.D., Britton,
1044 W.J., 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice
1045 underlie the heightened susceptibility to aerosol *Mycobacterium tuberculosis* infection,
1046 which is not compensated for by lymphotoxin. *Journal of Immunology (Baltimore, Md.:*
1047 *1950)* 162, 3504-3511.
- 1048 Behar, S.M., Divangahi, M., Remold, H.G., 2010. Evasion of innate immunity by
1049 *Mycobacterium tuberculosis*: is death an exit strategy? *Nature Reviews. Microbiology* 8,
1050 668-674.

1051 Behar, S.M., Martin, C.J., Booty, M.G., Nishimura, T., Zhao, X., Gan, H.X., Divangahi,
1052 M., Remold, H.G., 2011. Apoptosis is an innate defense function of macrophages against
1053 Mycobacterium tuberculosis. *Mucosal Immunology* 4, 279-287.

1054 Behr, M.A., Edelsein, P.H., Ramakrishnan, L. 2018. Revisiting the timetable of
1055 tuberculosis. *British Med J* 362:k2738.

1056 Belon, C., Gannoun-Zaki, L.Ø., Lutfalla, G., Kremer, L., Blanc-Potard, A.-B.a., 2014.
1057 Mycobacterium marinum MgtC plays a role in phagocytosis but is dispensable for
1058 intracellular multiplication. *PloS One* 9, e116052.

1059 Bengten, E., Wilson, M., 2015. Antibody Repertoires in Fish. *Results and Problems in*
1060 *Cell Differentiation* 57, 193-234.

1061 Bernut, A., Herrmann, J.L., Kissa, K., Dubremetz, J.F., Gaillard, J.L., Lutfalla, G.,
1062 Kremer, L., 2014. Mycobacterium abscessus cording prevents phagocytosis and promotes
1063 abscess formation. *Proc Natl Acad Sci U S A* 111, E943-952.

1064 Bernut, A., Herrmann, J.L., Ordway, D., Kremer, L., 2017. The Diverse Cellular and
1065 Animal Models to Decipher the Physiopathological Traits of Mycobacterium abscessus
1066 Infection. *Front Cell Infect Microbiol* 7, 100.

1067 Berrington, W.R., Hawn, T.R., 2007. Mycobacterium tuberculosis, macrophages, and the
1068 innate immune response: does common variation matter? *Immunological Reviews* 219,
1069 167-186.

1070 Best, S.M., 2008. Viral subversion of apoptotic enzymes: escape from death row. *Annual*
1071 *Review of Microbiology* 62, 171-192.

1072 Blomgran, R., Desvignes, L., Briken, V., Ernst, J.D., 2012. Mycobacterium tuberculosis
1073 Inhibits Neutrophil Apoptosis, Leading to Delayed Activation of Naive CD4 T⁺ cells.
1074 *Cell Host & Microbe* 11, 81-90.

1075 Boehm, U., Klamp, T., Groot, M., Howard, J.C., 1997. Cellular responses to interferon-
1076 gamma. *Annual Review of Immunology* 15, 749-795.

1077 Botha, T., Ryffel, B., 2003. Reactivation of latent tuberculosis infection in TNF-deficient
1078 mice. *Journal of Immunology (Baltimore, Md.: 1950)* 171, 3110-3118.

1079 Cambier, C.J., Takaki, K.K., Larson, R.P., Hernandez, R.E., Tobin, D.M., Urdahl, K.B.,
1080 Cosma, C.L., Ramakrishnan, L., 2014. Mycobacteria manipulate macrophage recruitment
1081 through coordinated use of membrane lipids. *Nature* 505, 218-222.

1082 Campbell, I.A., Bah-Sow, O., 2006. Pulmonary tuberculosis: diagnosis and treatment.
1083 *BMJ : British Medical Journal* 332, 1194-1197.

1084 Carmona, J., Cruz, A., Moreira-Teixeira, L., Sousa, C., Sousa, J., Osorio, N.S., Saraiva,
1085 A.L., Svenson, S., Kallenius, G., Pedrosa, J., Rodrigues, F., Castro, A.G., Saraiva, M.,
1086 2013. Mycobacterium tuberculosis Strains Are Differentially Recognized by TLRs with
1087 an Impact on the Immune Response. *PloS One* 8, e67277.

1088 Castro, R., Takizawa, F., Chacara, W., Lunazzi, A.I., Dang, T.H., Koellner, B., Quillet, E.,
1089 Six, A., Fischer, U., Boudinot, P., 2013. Contrasted TCR β Diversity of CD8⁺ and CD8⁻
1090 T Cells in Rainbow Trout. *PLOS ONE* 8, e60175.

1091 Caws, M., Thwaites, G., Dunstan, S., Hawn, T.R., Lan, N.T.N., Thuong, N.T.T.,
1092 Stepniewska, K., Huyen, M.N.T., Bang, N.D., Loc, T.H., Gagneux, S., van Soolingen, D.,
1093 Kremer, K., van der Sande, M., Small, P., Anh, P.T.H., Chinh, N.T., Quy, H.T., Duyen,
1094 N.T.H., Tho, D.Q., Hieu, N.T., Torok, E., Hien, T.T., Dung, N.H., Nhu, N.T.Q., Duy,
1095 P.M., van Vinh Chau, N., Farrar, J., 2008. The influence of host and bacterial genotype

1096 on the development of disseminated disease with *Mycobacterium tuberculosis*. *PLoS*
1097 *pathogens* 4, e1000034.

1098 Chakravarty, S.D., Zhu, G., Tsai, M.C., Mohan, V.P., Marino, S., Kirschner, D.E., Huang,
1099 L., Flynn, J., Chan, J., 2008. Tumor necrosis factor blockade in chronic murine
1100 tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the
1101 lungs. *Infection and Immunity* 76, 916-926.

1102 Chang, J.C., Wysocki, A., Tchou-Wong, K.M., Moskowitz, N., Zhang, Y., Rom, W.N.,
1103 1996. Effect of *Mycobacterium tuberculosis* and its components on macrophages and the
1104 release of matrix metalloproteinases. *Thorax* 51, 306-311.

1105 Cheeseman, E.A., 1952. The age distribution of tuberculosis mortality in Northern
1106 Ireland. *The Ulster Medical Journal* 21, 15-24.

1107 Chen, M., Divangahi, M., Gan, H., Shin, D.S.J., Hong, S., Lee, D.M., Serhan, C.N.,
1108 Behar, S.M., Remold, H.G., 2008. Lipid mediators in innate immunity against
1109 tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death.
1110 *The Journal of Experimental Medicine* 205, 2791-2801.

1111 Chen, Z., Hu, Y., Cumming, B.M., Lu, P., Feng, L., Deng, J., Steyn, A.J., Chen, S.,
1112 2016a. Mycobacterial WhiB6 Differentially Regulates ESX-1 and the Dos Regulon to
1113 Modulate Granuloma Formation and Virulence in Zebrafish. *Cell Rep* 16, 2512-2524.

1114 Chen, Z., Hu, Y., Cumming, B.M., Lu, P., Feng, L., Deng, J., Steyn, A.J.C., Chen, S.,
1115 2016b. Mycobacterial WhiB6 Differentially Regulates ESX-1 and the Dos Regulon to
1116 Modulate Granuloma Formation and Virulence in Zebrafish. *Cell Reports* 16, 2512-2524.

1117 Clay, H., Davis, J.M., Beery, D., Huttenlocher, A., Lyons, S.E., Ramakrishnan, L., 2007.
1118 Dichotomous Role of the Macrophage in Early *Mycobacterium marinum* Infection of the
1119 Zebrafish. *Cell Host & Microbe* 2, 29-39.

1120 Clay, H., Volkman, H.E., Ramakrishnan, L., 2008. Tumor Necrosis Factor Signaling
1121 Mediates Resistance to Mycobacteria by Inhibiting Bacterial Growth and Macrophage
1122 Death. *Immunity* 29, 283-294.

1123 Clemens, D.L., Horwitz, M.A., 1996. The *Mycobacterium tuberculosis* phagosome
1124 interacts with early endosomes and is accessible to exogenously administered transferrin.
1125 *The Journal of Experimental Medicine* 184, 1349-1355.

1126 Colditz, G.A., Brewer, T.F., Berkey, C.S., Wilson, M.E., Burdick, E., Fineberg, H.V.,
1127 Mosteller, F., 1994. Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-
1128 analysis of the Published Literature. *JAMA* 271, 698-702.

1129 Comstock, G.W., Livesay, V.T., Woolpert, S.F., 1974. The prognosis of a positive
1130 tuberculin reaction in childhood and adolescence. *American Journal of Epidemiology* 99,
1131 131-138.

1132 Cooper, A.M., 2009. Cell-mediated immune responses in tuberculosis. *Annual Review of*
1133 *Immunology* 27, 393-422.

1134 Cooper, A.M., Dalton, D.K., Stewart, T.A., Griffin, J.P., Russell, D.G., Orme, I.M., 1993.
1135 Disseminated tuberculosis in interferon gamma gene-disrupted mice. *Journal of*
1136 *Experimental Medicine* 178, 2243-2247.

1137 Cooper, A.M., Segal, B.H., Frank, A.A., Holland, S.M., Orme, I.M., 2000. Transient loss
1138 of resistance to pulmonary tuberculosis in p47(phox^{-/-}) mice. *Infection and Immunity* 68,
1139 1231-1234.

1140 Cooper Andrea, M., Khader Shabaana, A., 2008. The role of cytokines in the initiation,
1141 expansion, and control of cellular immunity to tuberculosis. *Immunological Reviews* 226,
1142 191-204.

1143 Cosma, C.L., Sherman, D.R., Ramakrishnan, L., 2003. The secret lives of the pathogenic
1144 mycobacteria. *Annual Review of Microbiology* 57, 641-676.

1145 Cronan, M.R., Beerman, R.W., Rosenberg, A.F., Saelens, J.W., Johnson, M.G., Oehlers,
1146 S.H., Sisk, D.M., Jurcic Smith, K.L., Medvitz, N.A., Miller, S.E., Trinh, L.A., Fraser,
1147 S.E., Madden, J.F., Turner, J., Stout, J.E., Lee, S., Tobin, D.M., 2016. Macrophage
1148 Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes
1149 Infection. *Immunity* 45, 861-876.

1150 Cui, Z., Samuel-Shaker, D., Watral, V., Kent, M.L., 2010. Attenuated *Mycobacterium*
1151 *marinum* protects zebrafish against mycobacteriosis. *Journal of Fish Diseases* 33, 371-
1152 375.

1153 Curtis, J., Kopanitsa, L., Stebbings, E., Speirs, A., Ignatyeva, O., Balabanova, Y.,
1154 Nikolayevskyy, V., Hoffner, S., Horstmann, R., Drobniowski, F., Nejentsev, S., 2011.
1155 Association analysis of the LTA4H gene polymorphisms and pulmonary tuberculosis in
1156 9115 subjects. *Tuberculosis (Edinburgh, Scotland)* 91, 22-25.

1157 Daniel, T.M., 2005. Robert Koch and the pathogenesis of tuberculosis. *The International*
1158 *Journal of Tuberculosis and Lung Disease: The Official Journal of the International*
1159 *Union Against Tuberculosis and Lung Disease* 9, 1181-1182.

1160 Daniel, T.M., 2006. The history of tuberculosis. *Respiratory Medicine* 100, 1862-1870.

1161 Darrah, P.A., Patel, D.T., De Luca, P.M., Lindsay, R.W.B., Davey, D.F., Flynn, B.J.,
1162 Hoff, S.r.T., Andersen, P., Reed, S.G., Morris, S.L., Roederer, M., Seder, R.A., 2007.
1163 Multifunctional TH1 cells define a correlate of vaccine-mediated protection against
1164 *Leishmania major*. *Nature Medicine* 13, 843-850.

1165 Davis, J.M., Clay, H., Lewis, J.L., Ghori, N., Herbomel, P., Ramakrishnan, L., 2002.
1166 Real-Time Visualization of *Mycobacterium*-Macrophage Interactions Leading to
1167 Initiation of Granuloma Formation in Zebrafish Embryos. *Immunity* 17, 693-702.

1168 Davis, J.M., Ramakrishnan, L., 2009. The Role of the Granuloma in Expansion and
1169 Dissemination of Early Tuberculous Infection. *Cell* 136, 37-49.

1170 Day, C.L., Abrahams, D.A., Lerumo, L., Janse van Rensburg, E., Stone, L., O'Rie, T.,
1171 Pienaar, B., de Kock, M., Kaplan, G., Mahomed, H., Dheda, K., Hanekom, W.A., 2011.
1172 Functional capacity of *Mycobacterium tuberculosis*-specific T cell responses in humans
1173 is associated with mycobacterial load. *Journal of Immunology (Baltimore, Md.: 1950)*
1174 187, 2222-2232.

1175 Day, C.L., Moshi, N.D., Abrahams, D.A., van Rooyen, M., O'Rie, T., de Kock, M.,
1176 Hanekom, W.A., 2014. Patients with tuberculosis disease have *Mycobacterium*
1177 *tuberculosis*-specific CD8 T cells with a pro-apoptotic phenotype and impaired
1178 proliferative capacity, which is not restored following treatment. *PloS One* 9, e94949.

1179 Dee, C.T., Nagaraju, R.T., Athanasiadis, E.I., Gray, C., Fernandez Del Ama, L., Johnston,
1180 S.A., Secombes, C.J., Cvejic, A., Hurlstone, A.F.L., 2016. CD4-Transgenic Zebrafish
1181 Reveal Tissue-Resident Th2- and Regulatory T Cell-like Populations and Diverse
1182 Mononuclear Phagocytes. *Journal of Immunology (Baltimore, Md.: 1950)* 197, 3520-
1183 3530.

1184 Deffert, C., Cachat, J., Krause, K.-H., 2014. Phagocyte NADPH oxidase, chronic
1185 granulomatous disease and mycobacterial infections. *Cellular Microbiology* 16, 1168-
1186 1178.

1187 den Boon, S., van Lill, S.W.P., Borgdorff, M.W., Enarson, D.A., Verver, S., Bateman,
1188 E.D., Irusen, E., Lombard, C.J., White, N.W., de Villiers, C., Beyers, N., 2007. High
1189 prevalence of tuberculosis in previously treated patients, Cape Town, South Africa.
1190 *Emerging Infectious Diseases* 13, 1189-1194.

1191 Divangahi, M., Desjardins, D., Nunes-Alves, C.u., Remold, H.G., Behar, S.M., 2010.
1192 Eicosanoid pathways regulate adaptive immunity to *Mycobacterium tuberculosis*. *Nature*
1193 *Immunology* 11, 751-758.

1194 Divangahi, M., Mostowy, S., Coulombe, F.o., Kozak, R., Guillot, L.Ø., Veyrier, F.d.r.,
1195 Kobayashi, K.S., Flavell, R.A., Gros, P., Behr, M.A., 2008. NOD2-deficient mice have
1196 impaired resistance to *Mycobacterium tuberculosis* infection through defective innate and
1197 adaptive immunity. *Journal of Immunology (Baltimore, Md.: 1950)* 181, 7157-7165.

1198 Dussurget, O., Stewart, G., Neyrolles, O., Pescher, P., Young, D., Marchal, G., 2001.
1199 Role of *Mycobacterium tuberculosis* copper-zinc superoxide dismutase. *Infection and*
1200 *Immunity* 69, 529-533.

1201 Early, J., Fischer, K., Bermudez, L.E., 2011. *Mycobacterium avium* uses apoptotic
1202 macrophages as tools for spreading. *Microbial Pathogenesis* 50, 132-139.

1203 Edwards, K.M., Cynamon, M.H., Voladri, R.K., Hager, C.C., DeStefano, M.S., Tham,
1204 K.T., Lakey, D.L., Bochan, M.R., Kernodle, D.S., 2001. Iron-cofactored superoxide
1205 dismutase inhibits host responses to *Mycobacterium tuberculosis*. *American Journal of*
1206 *Respiratory and Critical Care Medicine* 164, 2213-2219.

1207 Egen, J.G., Rothfuchs, A.G., Feng, C.G., Horwitz, M.A., Sher, A., Germain, R.N., 2011.
1208 Intravital imaging reveals limited antigen presentation and T cell effector function in
1209 mycobacterial granulomas. *Immunity* 34, 807-819.

1210 Ehrt, S., Schnappinger, D., 2009. Mycobacterial survival strategies in the phagosome:
1211 defence against host stresses. *Cellular Microbiology* 11, 1170-1178.

1212 El-Etr, S.H., Yan, L., Cirillo, J.D., 2001. Fish Monocytes as a Model for Mycobacterial
1213 Host-Pathogen Interactions. *Infection and Immunity* 69, 7310-7317.

1214 Elias, D., Britton, S., Aseffa, A., Engers, H., Akuffo, H., 2008. Poor immunogenicity of
1215 BCG in helminth infected population is associated with increased in vitro TGF-beta
1216 production. *Vaccine* 26, 3897-3902.

1217 Elks, P.M., Brizee, S., Vaart, M.v.d., Walmsley, S.R., Eeden, F.J.v., Renshaw, S.A.,
1218 Meijer, A.H., 2013. Hypoxia Inducible Factor Signaling Modulates Susceptibility to
1219 Mycobacterial Infection via a Nitric Oxide Dependent Mechanism. *PLOS Pathogens* 9,
1220 e1003789.

1221 Elks, P.M., Vaart, M.v.d., Hensbergen, V.v., Schutz, E., Redd, M.J., Murayama, E.,
1222 Spaink, H.P., Meijer, A.H., 2014. Mycobacteria Counteract a TLR-Mediated Nitrosative
1223 Defense Mechanism in a Zebrafish Infection Model. *PLOS ONE* 9, e100928.

1224 Eum, S.-Y., Kong, J.-H., Hong, M.-S., Lee, Y.-J., Kim, J.-H., Hwang, S.-H., Cho, S.-N.,
1225 Via, L.E., Barry, I.I.I.C.E., 2010. Neutrophils are the predominant infected phagocytic
1226 cells in the airways of patients with active pulmonary tb. *Chest* 137, 122-128.

1227 Fenaroli, F., Repnik, U., Xu, Y., Johann, K., Van Herck, S., Dey, P., Skjeldal, F.M., Frei,
1228 D.M., Bagherifam, S., Kocere, A., Haag, R., De Geest, B.G., Barz, M., Russell, D.G.,
1229 Griffiths, G., 2018. Enhanced Permeability and Retention-like Extravasation of

1230 Nanoparticles from the Vasculature into Tuberculosis Granulomas in Zebrafish and
1231 Mouse Models. *ACS Nano* 12, 8646-8661.

1232 Fenaroli, F., Westmoreland, D., Benjaminsen, J., Kolstad, T., Skjeldal, F.M., Meijer,
1233 A.H., van der Vaart, M., Ulanova, L., Roos, N., Nystrom, B., Hildahl, J., Griffiths, G.,
1234 2014. Nanoparticles as drug delivery system against tuberculosis in zebrafish embryos:
1235 direct visualization and treatment. *ACS Nano* 8, 7014-7026.

1236 Feoktistova, M., Leverkus, M., 2014. Programmed necrosis and necroptosis signalling.
1237 *The FEBS Journal* 282, 19-31.

1238 Fiorentino, D.F., Zlotnik, A., Vieira, P., Mosmann, T.R., Howard, M., Moore, K.W.,
1239 O'Garra, A., 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production
1240 by Th1 cells. *Journal of Immunology (Baltimore, Md.: 1950)* 146, 3444-3451.

1241 Flynn, J.L., Chan, J., 2001. Immunology of Tuberculosis. *Annual Review of Immunology*
1242 19, 93-129.

1243 Flynn, J.L., Chan, J., Triebold, K.J., Dalton, D.K., Stewart, T.A., Bloom, B.R., 1993. An
1244 essential role for interferon gamma in resistance to *Mycobacterium tuberculosis* infection.
1245 *The Journal of Experimental Medicine* 178, 2249-2254.

1246 Forrellad, M.A., Klepp, L.I., Gioffre, A., Garcia, J.S.y., Morbidoni, H.R., Santangelo,
1247 M.d.I.P., Cataldi, A.A., Bigi, F., 2013. Virulence factors of the *Mycobacterium*
1248 *tuberculosis* complex. *Virulence* 4, 3-66.

1249 Francis, R.J., Butler, R.E., Stewart, G.R., 2014. *Mycobacterium tuberculosis* ESAT-6 is a
1250 leukocidin causing Ca²⁺ influx, necrosis and neutrophil extracellular trap formation. *Cell*
1251 *Death & Disease* 5, e1474.

1252 Frieden, T.R., Sterling, T.R., Munsiff, S.S., Watt, C.J., Dye, C., 2003. Tuberculosis.
1253 *Lancet (London, England)* 362, 887-899.

1254 Gallegos, A.M., Pamer, E.G., Glickman, M.S., 2008. Delayed protection by ESAT-6-
1255 specific effector CD4⁺ T cells after airborne *M. tuberculosis* infection. *The Journal of*
1256 *Experimental Medicine* 205, 2359-2368.

1257 Gallegos, A.M., van Heijst, J.W.J., Samstein, M., Su, X., Pamer, E.G., Glickman, M.S.,
1258 2011. A gamma interferon independent mechanism of CD4 T cell mediated control of *M.*
1259 *tuberculosis* infection in vivo. *PLoS pathogens* 7, e1002052.

1260 Gautam, U.S., Foreman, T.W., Bucsan, A.N., Veatch, A.V., Alvarez, X., Adekambi, T.,
1261 Golden, N.A., Gentry, K.M., Doyle-Meyers, L.A., Russell-Lodrigue, K.E., Didier, P.J.,
1262 Blanchard, J.L., Kousoulas, K.G., Lackner, A.A., Kalman, D., Rengarajan, J., Khader,
1263 S.A., Kaushal, D., Mehra, S., 2018. In vivo inhibition of tryptophan catabolism
1264 reorganizes the tuberculoma and augments immune-mediated control of *Mycobacterium*
1265 *tuberculosis*. *Proc Natl Acad Sci U S A* 115, E62-E71.

1266 Gauthier, D.T., Rhodes, M.W., 2009. Mycobacteriosis in fishes: A review. *The*
1267 *Veterinary Journal* 180, 33-47.

1268 Gordon, S., 2003. Alternative activation of macrophages. *Nat Rev Immunol* 3, 23-35.

1269 Grayfer, L., Hodgkinson, J.W., Belosevic, M., 2011. Analysis of the antimicrobial
1270 responses of primary phagocytes of the goldfish (*Carassius auratus* L.) against
1271 *Mycobacterium marinum*. *Developmental & Comparative Immunology* 35, 1146-1158.

1272 Grayfer, L., Hodgkinson, J.W., Belosevic, M., 2014. Antimicrobial responses of teleost
1273 phagocytes and innate immune evasion strategies of intracellular bacteria. *Developmental*
1274 *& Comparative Immunology* 43, 223-242.

1275 Green, J., Rolfe, M.D., Smith, L.J., 2014. Transcriptional regulation of bacterial virulence
1276 gene expression by molecular oxygen and nitric oxide. *Virulence* 5, 794-809.

1277 Grohmann, U., Bronte, V., 2010. Control of immune response by amino acid metabolism.
1278 *Immunological Reviews* 236, 243-264.

1279 H. Herzog, B., 1998. History of Tuberculosis. *Respiration* 65, 5-15.

1280 Hall, C., Flores, M.V., Storm, T., Crosier, K., Crosier, P., 2007. The zebrafish lysozyme
1281 C promoter drives myeloid-specific expression in transgenic fish. *BMC Dev Biol* 7, 42.

1282 Hammaran, M.M., Oksanen, K.E., Nisula, H.M., Luukinen, B.V., Pesu, M., Ramet, M.,
1283 Parikka, M., 2014. Adequate Th2-Type Response Associates with Restricted Bacterial
1284 Growth in Latent Mycobacterial Infection of Zebrafish. *PLOS Pathogens* 10, e1004190.

1285 Harisinghani, M.G., McLoud, T.C., Shepard, J.A., Ko, J.P., Shroff, M.M., Mueller, P.R.,
1286 2000. Tuberculosis from head to toe. *Radiographics: A Review Publication of the*
1287 *Radiological Society of North America, Inc* 20, 449-470; quiz 528-529, 532.

1288 Harjula, S.E., Ojanen, M.J.T., Taavitsainen, S., Nykter, M., Ramet, M., 2018. Interleukin
1289 10 mutant zebrafish have an enhanced interferon gamma response and improved survival
1290 against a *Mycobacterium marinum* infection. *Sci Rep* 8, 10360.

1291 Harper, J., Skerry, C., Davis, S.L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W.R.,
1292 Pomper, M.G., Nuermberger, E.L., Jain, S.K., 2012. Mouse Model of Necrotic
1293 Tuberculosis Granulomas Develops Hypoxic Lesions. *The Journal of Infectious Diseases*
1294 205, 595-602.

1295 Henard, C.A., Vazquez-Torres, A.s., 2011. Nitric oxide and salmonella pathogenesis.
1296 *Frontiers in Microbiology* 2, 84.

1297 Herb, F., Thye, T., Niemann, S., Browne, E.N.L., Chinbuah, M.A., Gyapong, J., Osei, I.,
1298 Owusu-Dabo, E., Werz, O., Rusch-Gerdes, S., Horstmann, R.D., Meyer, C.G., 2008.
1299 ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. *Human*
1300 *Molecular Genetics* 17, 1052-1060.

1301 Hernandez-Pando, R., Orozco, H., Arriaga, K., Pavon, L., Rook, G., 2000. Treatment
1302 with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes
1303 deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis
1304 in Balb/c mice. *Int J Exp Pathol* 81, 199-209.

1305 Hinchey, J., Lee, S., Jeon, B.Y., Basaraba, R.J., Venkataswamy, M.M., Chen, B., Chan, J.,
1306 Braunstein, M., Orme, I.M., Derrick, S.C., Morris, S.L., Jacobs, W.R., Porcelli, S.A.,
1307 2007. Enhanced priming of adaptive immunity by a proapoptotic mutant of
1308 *Mycobacterium tuberculosis*. *The Journal of Clinical Investigation* 117, 2279-2288.

1309 Hines, M.E., Kreeger, J.M., Herron, A.J., 1995. Mycobacterial infections of animals:
1310 pathology and pathogenesis. *Laboratory Animal Science* 45, 334-351.

1311 Hodgkinson, J.W., Fibke, C., Belosevic, M., 2017. Recombinant IL-4/13A and IL-4/13B
1312 induce arginase activity and down-regulate nitric oxide response of primary goldfish
1313 (*Carassius auratus* L.) macrophages. *Developmental & Comparative Immunology* 67,
1314 377-384.

1315 Hodgkinson, J.W., Ge, J.-Q., Grayfer, L., Stafford, J., Belosevic, M., 2012. Analysis of
1316 the immune response in infections of the goldfish (*Carassius auratus* L.) with
1317 *Mycobacterium marinum*. *Developmental and comparative immunology* 38, 456-465.

1318 Hodgkinson, J.W., Ge, J.Q., Katzenback, B.A., Havixbeck, J.J., Barreda, D.R., Stafford,
1319 J.L., Belosevic, M., 2015. Development of an in vitro model system to study the

1320 interactions between *Mycobacterium marinum* and teleost neutrophils. *Dev Comp*
1321 *Immunol* 53, 349-357.

1322 Hosseini, R., Lamers, G.E., Soltani, H.M., Meijer, A.H., Spaank, H.P., Schaaf, M.J., 2016.
1323 Efferocytosis and extrusion of leukocytes determine the progression of early
1324 mycobacterial pathogenesis. *J Cell Sci* 129, 3385-3395.

1325 Huang, X., Wang, H., Meng, L., Wang, Q., Yu, J., Gao, Q., Wang, D., 2016. Role of
1326 eosinophils and apoptosis in PDIMs/PGLs deficient mycobacterium elimination in adult
1327 zebrafish. *Developmental and Comparative Immunology* 59, 199-206.

1328 Hui, S.P., Sheng, D.Z., Sugimoto, K., Gonzalez-Rajal, A., Nakagawa, S., Hesselton, D.,
1329 Kikuchi, K., 2017. Zebrafish Regulatory T Cells Mediate Organ-Specific Regenerative
1330 Programs. *Dev Cell* 43, 659-672 e655.

1331 Hunter, R.L., 2011. Pathology of post primary tuberculosis of the lung: an illustrated
1332 critical review. *Tuberculosis (Edinburgh, Scotland)* 91, 497-509.

1333 Hunter, R.L., Actor, J.K., Hwang, S.-A., Khan, A., Urbanowski, M.E., Kaushal, D.,
1334 Jagannath, C., 2018. Pathogenesis and Animal Models of Post-Primary (Bronchogenic)
1335 Tuberculosis, A Review. *Pathogens* 7, 19.

1336 Iliopoulos, A., Psathakis, K., Aslanidis, S., Skagias, L., Sfikakis, P.P., 2006. Tuberculosis
1337 and granuloma formation in patients receiving anti-TNF therapy. *The International*
1338 *Journal of Tuberculosis and Lung Disease: The Official Journal of the International*
1339 *Union Against Tuberculosis and Lung Disease* 10, 588-590.

1340 Jacob, J.T., Mehta, A.K., Leonard, M.K., 2009. Acute Forms of Tuberculosis in Adults.
1341 *The American Journal of Medicine* 122, 12-17.

1342 Jacobs, J.M., Stine, C.B., Baya, A.M., Kent, M.L., 2009. A review of mycobacteriosis in
1343 marine fish. *Journal of Fish Diseases* 32, 119-130.

1344 Jaeger, T., Budde, H., Flohe, L., Menge, U., Singh, M., Trujillo, M., Radi, R., 2004.
1345 Multiple thioredoxin-mediated routes to detoxify hydroperoxides in *Mycobacterium*
1346 *tuberculosis*. *Archives of Biochemistry and Biophysics* 423, 182-191.

1347 Jasenosky Luke, D., Scriba Thomas, J., Hanekom Willem, A., Goldfeld Anne, E., 2015.
1348 T cells and adaptive immunity to *Mycobacterium tuberculosis* in humans. *Immunological*
1349 *Reviews* 264, 74-87.

1350 Jayakumar, D., Jacobs, W.R., Narayanan, S., 2008. Protein kinase E of *Mycobacterium*
1351 *tuberculosis* has a role in the nitric oxide stress response and apoptosis in a human
1352 macrophage model of infection. *Cellular Microbiology* 10, 365-374.

1353 Joerink, M., Ribeiro, C.M.S., Stet, R.J.M., Hermsen, T., Savelkoul, H.F.J., Wiegertjes,
1354 G.F., 2006. Head Kidney-Derived Macrophages of Common Carp (*Cyprinus carpio* L.)
1355 Show Plasticity and Functional Polarization upon Differential Stimulation. *The Journal of*
1356 *Immunology* 177, 61-69.

1357 Johansen, M.D., Kasparian, J.A., Hortle, E., Britton, W.J., Purdie, A.C., Oehlers, S.H.,
1358 2018. *Mycobacterium marinum* infection drives foam cell differentiation in zebrafish
1359 infection models. *Dev Comp Immunol* 88, 169-172.

1360 Jonsson, B.E., Gilljam, M., Lindblad, A., Ridell, M., Wold, A.E., Welinder-Olsson, C.,
1361 2007. Molecular epidemiology of *Mycobacterium abscessus*, with focus on cystic fibrosis.
1362 *J Clin Microbiol* 45, 1497-1504.

1363 Jouanguy, E., Lamhamedi-Cherradi, S., Altare, F., Fondanache, M.C., Tuerlinckx, D.,
1364 Blanche, S., Emile, J.F., Gaillard, J.L., Schreiber, R., Levin, M., Fischer, A., Hivroz, C.,
1365 Casanova, J.L., 1997. Partial interferon-gamma receptor 1 deficiency in a child with

1366 tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis.
1367 The Journal of Clinical Investigation 100, 2658-2664.

1368 Jung, Y.J., LaCourse, R., Ryan, L., North, R.J., 2002. Virulent but not avirulent
1369 Mycobacterium tuberculosis can evade the growth inhibitory action of a T helper 1-
1370 dependent, nitric oxide Synthase 2-independent defense in mice. J Exp Med 196, 991-998.

1371 Kagina, B.M.N., Abel, B., Scriba, T.J., Hughes, E.J., Keyser, A., Soares, A., Gamielien,
1372 H., Sidibana, M., Hatherill, M., Gelderbloem, S., Mahomed, H., Hawkrige, A., Hussey,
1373 G., Kaplan, G., Hanekom, W.A., other members of the South African Tuberculosis
1374 Vaccine, I., 2010. Specific T cell frequency and cytokine expression profile do not
1375 correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination
1376 of newborns. American Journal of Respiratory and Critical Care Medicine 182, 1073-
1377 1079.

1378 Kasheta, M., Painter, C.A., Moore, F.E., Lobbardi, R., Bryll, A., Freiman, E., Stachura,
1379 D., Rogers, A.B., Houvras, Y., Langenau, D.M., Ceol, C.J., 2017. Identification and
1380 characterization of T reg-like cells in zebrafish. J Exp Med 214, 3519-3530.

1381 Keane, J., Remold, H.G., Kornfeld, H., 2000. Virulent Mycobacterium tuberculosis
1382 strains evade apoptosis of infected alveolar macrophages. Journal of Immunology
1383 (Baltimore, Md.: 1950) 164, 2016-2020.

1384 Kelly, D.M., ten Bokum, A.M.C., O'Leary, S.M., O'Sullivan, M.P., Keane, J., 2008.
1385 Bystander macrophage apoptosis after Mycobacterium tuberculosis H37Ra infection.
1386 Infection and Immunity 76, 351-360.

1387 Khader, S.A., Partida-Sanchez, S., Bell, G., Jelley-Gibbs, D.M., Swain, S., Pearl, J.E.,
1388 Ghilardi, N., Desauvage, F.J., Lund, F.E., Cooper, A.M., 2006. Interleukin 12p40 is
1389 required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis
1390 infection. The Journal of Experimental Medicine 203, 1805-1815.

1391 Khader, S.A., Pearl, J.E., Sakamoto, K., Gilmartin, L., Bell, G.K., Jelley-Gibbs, D.M.,
1392 Ghilardi, N., deSauvage, F., Cooper, A.M., 2005. IL-23 compensates for the absence of
1393 IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for
1394 protection and antigen-specific IFN-gamma responses if IL-12p70 is available. Journal of
1395 Immunology (Baltimore, Md.: 1950) 175, 788-795.

1396 Kleinnijenhuis, J., Oosting, M., Joosten, L.A.B., Netea, M.G., Van Crevel, R., 2011.
1397 Innate immune recognition of Mycobacterium tuberculosis. Clinical & Developmental
1398 Immunology 2011, 405310.

1399 Koch, R., 1952. [Tuberculosis etiology]. Das Deutsche Gesundheitswesen 7, 457-465.

1400 Kumararatne, D.S., 1997. Tuberculosis and immunodeficiency--of mice and men.
1401 Clinical and Experimental Immunology 107, 11-14.

1402 Kunkel, S.L., Chensue, S.W., Strieter, R.M., Lynch, J.P., Remick, D.G., 1989. Cellular
1403 and molecular aspects of granulomatous inflammation. American Journal of Respiratory
1404 Cell and Molecular Biology 1, 439-447.

1405 Kursar, M., Koch, M., Mittracker, H.-W., Nouailles, G., Bonhagen, K., Kamradt, T.,
1406 Kaufmann, S.H.E., 2007. Cutting Edge: Regulatory T Cells Prevent Efficient Clearance
1407 of Mycobacterium tuberculosis. The Journal of Immunology 178, 2661-2665.

1408 Lawn, S.D., Acheampong, J.W., 1999. Pulmonary tuberculosis in adults: factors
1409 associated with mortality at a Ghanaian teaching hospital. West African Journal of
1410 Medicine 18, 270-274.

1411 Leibovitz, L., 1980. Fish tuberculosis (mycobacteriosis). *Journal of the American*
1412 *Veterinary Medical Association* 176, 415.

1413 Levitte, S., Adams, K.N., Berg, R.D., Cosma, C.L., Urdahl, K.B., Ramakrishnan, L.,
1414 2016. Mycobacterial Acid Tolerance Enables Phagolysosomal Survival and
1415 Establishment of Tuberculous Infection In Vivo. *Cell Host Microbe* 20, 250-258.

1416 Lin, P.L., Myers, A., Smith, L.K., Bigbee, C., Bigbee, M., Fuhrman, C., Grieser, H.,
1417 Chiosea, I., Voitenek, N.N., Capuano, S.V., Klein, E., Flynn, J.L., 2010. Tumor necrosis
1418 factor neutralization results in disseminated disease in acute and latent *Mycobacterium*
1419 tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.
1420 *Arthritis and Rheumatism* 62, 340-350.

1421 Lowe, D.M., Bandara, A.K., Packe, G.E., Barker, R.D., Wilkinson, R.J., Griffiths, C.J.,
1422 Martineau, A.R., 2013. Neutrophilia independently predicts death in tuberculosis. *The*
1423 *European respiratory journal* 42, 1752-1757.

1424 Lu, L.L., Chung, A.W., Rosebrock, T.R., Ghebremichael, M., Yu, W.H., Grace, P.S.,
1425 Schoen, M.K., Tafesse, F., Martin, C., Leung, V., Mahan, A.E., Sips, M., Kumar, M.P.,
1426 Tedesco, J., Robinson, H., Tkachenko, E., Draghi, M., Freedberg, K.J., Streeck, H.,
1427 Suscovich, T.J., Lauffenburger, D.A., Restrepo, B.I., Day, C., Fortune, S.M., Alter, G.,
1428 2016. A Functional Role for Antibodies in Tuberculosis. *Cell* 167, 433-443 e414.

1429 MacMicking, J.D., North, R.J., LaCourse, R., Mudgett, J.S., Shah, S.K., Nathan, C.F.,
1430 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis.
1431 *Proceedings of the National Academy of Sciences of the United States of America* 94,
1432 5243-5248.

1433 Madigan, C.A., Cambier, C.J., Kelly-Scumpia, K.M., Scumpia, P.O., Cheng, T.Y., Zailaa,
1434 J., Bloom, B.R., Moody, D.B., Smale, S.T., Sagasti, A., Modlin, R.L., Ramakrishnan, L.,
1435 2017a. A Macrophage Response to *Mycobacterium leprae* Phenolic Glycolipid Initiates
1436 Nerve Damage in Leprosy. *Cell* 170, 973-985 e910.

1437 Madigan, C.A., Cameron, J., Ramakrishnan, L., 2017b. A Zebrafish Model of
1438 *Mycobacterium leprae* Granulomatous Infection. *J Infect Dis* 216, 776-779.

1439 Maglione Paul, J., Chan, J., 2009. How B cells shape the immune response against
1440 *Mycobacterium tuberculosis*. *European Journal of Immunology* 39, 676-686.

1441 Maglione, P.J., Xu, J., Chan, J., 2007. B cells moderate inflammatory progression and
1442 enhance bacterial containment upon pulmonary challenge with *Mycobacterium*
1443 tuberculosis. *Journal of Immunology (Baltimore, Md.: 1950)* 178, 7222-7234.

1444 Malcolm, K.C., Caceres, S.M., Pohl, K., Poch, K.R., Bernut, A., Kremer, L., Bratton,
1445 D.L., Herrmann, J.L., Nick, J.A., 2018. Neutrophil killing of *Mycobacterium abscessus*
1446 by intra- and extracellular mechanisms. *PLOS ONE* 13, e0196120.

1447 Martin, C.J., Booty, M.G., Rosebrock, T.R., Nunes-Alves, C.u., Desjardins, D.M., Keren,
1448 I., Fortune, S.M., Remold, H.G., Behar, S.M., 2012. Efferocytosis is an innate
1449 antibacterial mechanism. *Cell Host & Microbe* 12, 289-300.

1450 Meijer, A.H., van der Vaart, M., 2014. DRAM1 promotes the targeting of mycobacteria
1451 to selective autophagy. *Autophagy* 10, 2389-2391.

1452 Mohan, V.P., Scanga, C.A., Yu, K., Scott, H.M., Tanaka, K.E., Tsang, E., Tsai, M.C.,
1453 Flynn, J.L., Chan, J., 2001. Effects of Tumor Necrosis Factor Alpha on Host Immune
1454 Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology.
1455 *Infection and Immunity* 69, 1847-1855.

1456 Mohanty, S., Jagannathan, L., Ganguli, G., Padhi, A., Roy, D., Alaridah, N., Saha, P.,
1457 Nongthomba, U., Godaly, G., Gopal, R.K., Banerjee, S., Sonawane, A., 2015. A
1458 Mycobacterial Phosphoribosyltransferase Promotes Bacillary Survival by Inhibiting
1459 Oxidative Stress and Autophagy Pathways in Macrophages and Zebrafish. *Journal of*
1460 *Biological Chemistry* 290, 13321-13343.
1461 Moore, K.W., de Waal Malefyt, R., Coffman, R.L., O'Garra, A., 2001. Interleukin-10 and
1462 the interleukin-10 receptor. *Annual Review of Immunology* 19, 683-765.
1463 Myllymaki, H., Niskanen, M., Luukinen, H., Parikka, M., Ramet, M., 2018. Identification
1464 of protective postexposure mycobacterial vaccine antigens using an immunosuppression-
1465 based reactivation model in the zebrafish. *Disease Models & Mechanisms* 11,
1466 dmm033175.
1467 Myllymaki, H., Niskanen, M., Oksanen, K.E., Sherwood, E., Ahava, M., Parikka, M.,
1468 Ramet, M., 2017. Identification of novel antigen candidates for a tuberculosis vaccine in
1469 the adult zebrafish (*Danio rerio*). *PLOS ONE* 12, e0181942.
1470 Nandi, B., Behar, S.M., 2011. Regulation of neutrophils by interferon- γ limits lung
1471 inflammation during tuberculosis infection. *The Journal of Experimental Medicine* 208,
1472 2251-2262.
1473 Ng, V.H., Cox, J.S., Sousa, A.O., MacMicking, J.D., McKinney, J.D., 2004. Role of
1474 KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte
1475 oxidative burst. *Molecular Microbiology* 52, 1291-1302.
1476 North, R.J., Jung, Y.-J., 2004. Immunity to tuberculosis. *Annual Review of Immunology*
1477 22, 599-623.
1478 Nunez Ortiz, N., Gerdol, M., Stocchi, V., Marozzi, C., Randelli, E., Bernini, C.,
1479 Buonocore, F., Picchietti, S., Papeschi, C., Sood, N., Pallavicini, A., Scapigliati, G., 2014.
1480 T cell transcripts and T cell activities in the gills of the teleost fish sea bass
1481 (*Dicentrarchus labrax*). *Developmental & Comparative Immunology* 47, 309-318.
1482 O'Leary, S.n., O'Sullivan, M.P., Keane, J., 2011. IL-10 blocks phagosome maturation in
1483 mycobacterium tuberculosis-infected human macrophages. *American Journal of*
1484 *Respiratory Cell and Molecular Biology* 45, 172-180.
1485 Oehlers, S.H., Cronan, M.R., Beerman, R.W., Johnson, M.G., Huang, J., Kontos, C.D.,
1486 Stout, J.E., Tobin, D.M., 2017. Infection-Induced Vascular Permeability Aids
1487 Mycobacterial Growth. *J Infect Dis* 215, 813-817.
1488 Oehlers, S.H., Cronan, M.R., Scott, N.R., Thomas, M.I., Okuda, K.S., Walton, E.M.,
1489 Beerman, R.W., Crosier, P.S., Tobin, D.M., 2015. Interception of host angiogenic
1490 signalling limits mycobacterial growth. *Nature* 517, 612-615.
1491 Ogryzko, N.V., Lewis A., Wilson H.L., Meijer A.H., Renshaw S.A., Elks P.M., 2018.
1492 Hif-1 α -induced expression of Il-1 β protects against mycobacterial infection in zebrafish.
1493 *J Immunol.* pii: ji1801139. doi: 10.4049
1494 Ojanen, M.J.T., Turpeinen, H., Cordova, Z.M., Hammaren, M.M., Harjula, S.-K.E.,
1495 Parikka, M., Ramet, M., Pesu, M., 2015. The Proprotein Convertase Subtilisin/Kexin
1496 FurinA Regulates Zebrafish Host Response against Mycobacterium marinum. *Infection*
1497 and *Immunity* 83, 1431-1442.
1498 Oksanen, K.E., Halfpenny, N.J.A., Sherwood, E., Harjula, S.-K.E., Hammaren, M.M.,
1499 Ahava, M.J., Pajula, E.T., Lahtinen, M.J., Parikka, M., Ramet, M., 2013. An adult
1500 zebrafish model for preclinical tuberculosis vaccine development. *Vaccine* 31, 5202-5209.

1501 Oksanen, K.E., Myllymaki, H., Ahava, M.J., Makinen, L., Parikka, M., Ramet, M., 2016.
1502 DNA vaccination boosts *Bacillus Calmette-Guerin* protection against mycobacterial
1503 infection in zebrafish. *Dev Comp Immunol* 54, 89-96.

1504 Pagan, A.J., Ramakrishnan, L., 2015. Immunity and Immunopathology in the
1505 Tuberculous Granuloma. *Cold Spring Harbor Perspectives in Medicine* 5, a018499.

1506 Paige, C., Bishai, W.R., 2010. Penitentiary or penthouse condo: the tuberculous
1507 granuloma from the microbe's point of view. *Cellular Microbiology* 12, 301-309.

1508 Parikka, M., Hammaren, M.M., Harjula, S.-K.E., Halfpenny, N.J.A., Oksanen, K.E.,
1509 Lahtinen, M.J., Pajula, E.T., Iivanainen, A., Pesu, M., Ramet, M., 2012. *Mycobacterium*
1510 *marinum* Causes a Latent Infection that Can Be Reactivated by Gamma Irradiation in
1511 Adult Zebrafish. *PLoS Pathog* 8, e1002944.

1512 Pasnik, D.J., Vemulapalli, R., Smith, S.A., Schurig, G.G., 2003. A recombinant vaccine
1513 expressing a mammalian *Mycobacterium* sp. antigen is immunostimulatory but not
1514 protective in striped bass. *Veterinary Immunology and Immunopathology* 95, 43-52.

1515 Peters, W., Ernst, J.D., 2003. Mechanisms of cell recruitment in the immune response to
1516 *Mycobacterium tuberculosis*. *Microbes and Infection* 5, 151-158.

1517 Petrini, B., 2006. *Mycobacterium marinum*: ubiquitous agent of waterborne
1518 granulomatous skin infections. *European Journal of Clinical Microbiology & Infectious*
1519 *Diseases: Official Publication of the European Society of Clinical Microbiology* 25, 609-
1520 613.

1521 Phuah, J.Y., Mattila, J.T., Lin, P.L., Flynn, J.L., 2012. Activated B cells in the
1522 granulomas of nonhuman primates infected with *Mycobacterium tuberculosis*. *The*
1523 *American Journal of Pathology* 181, 508-514.

1524 Piddington, D.L., Fang, F.C., Laessig, T., Cooper, A.M., Orme, I.M., Buchmeier, N.A.,
1525 2001. Cu,Zn superoxide dismutase of *Mycobacterium tuberculosis* contributes to survival
1526 in activated macrophages that are generating an oxidative burst. *Infection and Immunity*
1527 69, 4980-4987.

1528 Plain, K.M., de Silva, K., Earl, J., Begg, D.J., Purdie, A.C., Whittington, R.J., 2011.
1529 Indoleamine 2,3-Dioxygenase, Tryptophan Catabolism, and *Mycobacterium avium* subsp.
1530 *paratuberculosis*: a Model for Chronic Mycobacterial Infections. *Infection and*
1531 *Immunity* 79, 3821-3832.

1532 Portevin, D., Sukumar, S., Coscolla, M., Shui, G., Li, B., Guan, X.L., Bendt, A.K.,
1533 Young, D., Gagneux, S., Wenk, M.R., 2014. Lipidomics and genomics of
1534 *Mycobacterium tuberculosis* reveal lineage-specific trends in mycolic acid biosynthesis.
1535 *MicrobiologyOpen* 3, 823-835.

1536 Potian, J.A., Rafi, W., Bhatt, K., McBride, A., Gause, W.C., Salgame, P., 2011.
1537 Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis
1538 defense by engaging the IL-4 receptor pathway. *Journal of Experimental Medicine* 208,
1539 1863-1874.

1540 Price, N.M., Farrar, J., Tran, T.T., Nguyen, T.H., Tran, T.H., Friedland, J.S., 2001.
1541 Identification of a matrix-degrading phenotype in human tuberculosis *in vitro* and *in vivo*.
1542 *J Immunol* 166, 4223-4230.

1543 Ramakrishnan, L., 2013. Looking Within the Zebrafish to Understand the Tuberculous
1544 Granuloma, *The New Paradigm of Immunity to Tuberculosis*. Springer, New York, NY,
1545 pp. 251-266.

1546 Redford, P.S., Boonstra, A., Read, S., Pitt, J., Graham, C., Stavropoulos, E., Bancroft,
1547 G.J., O'Garra, A., 2010. Enhanced protection to Mycobacterium tuberculosis infection in
1548 IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung.
1549 *European Journal of Immunology* 40, 2200-2210.

1550 Reed, M.B., Domenech, P., Manca, C., Su, H., Barczak, A.K., Kreiswirth, B.N., Kaplan,
1551 G., Barry, C.E., 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the
1552 innate immune response. *Nature* 431, 84-87.

1553 Reiling, N., Ehlers, S., Holscher, C., 2008. MyDths and un-TOLled truths: sensor,
1554 instructive and effector immunity to tuberculosis. *Immunology Letters* 116, 15-23.

1555 Resende Co, T., Hirsch, C.S., Toossi, Z., Dietze, R., Ribeiro-Rodrigues, R., 2007.
1556 Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium
1557 tuberculosis immunity and clinical response to tuberculosis therapy. *Clinical and*
1558 *Experimental Immunology* 147, 45-52.

1559 Roach, D.R., Martin, E., Bean, A.G., Rennick, D.M., Briscoe, H., Britton, W.J., 2001.
1560 Endogenous inhibition of antimycobacterial immunity by IL-10 varies between
1561 mycobacterial species. *Scandinavian Journal of Immunology* 54, 163-170.

1562 Roca, F.J., Ramakrishnan, L., 2013. TNF Dually Mediates Resistance and Susceptibility
1563 to Mycobacteria via Mitochondrial Reactive Oxygen Species. *Cell* 153, 521-534.

1564 Romagnani, S., 1999. Th1/Th2 cells. *Inflammatory Bowel Diseases* 5, 285-294.

1565 Rossouw, M., Nel, H.J., Cooke, G.S., van Helden, P.D., Hoal, E.G., 2003. Association
1566 between tuberculosis and a polymorphic NFKappaB binding site in the interferon gamma
1567 gene. *Lancet (London, England)* 361, 1871-1872.

1568 Rowe, H.M., Withey, J.H., Neely, M.N., 2014. Zebrafish as a model for zoonotic aquatic
1569 pathogens. *Developmental and Comparative Immunology* 46, 96-107.

1570 Runyon, E.H., 1959. Anonymous mycobacteria in pulmonary disease. *The Medical*
1571 *Clinics of North America* 43, 273-290.

1572 Russell, D.G., VanderVen, B.C., Lee, W., Abramovitch, R.B., Kim, M.-j., Homolka, S.,
1573 Niemann, S., Rohde, K.H., 2010. Mycobacterium tuberculosis wears what it eats. *Cell*
1574 *Host & Microbe* 8, 68-76.

1575 Saraiva, M., O'Garra, A., 2010. The regulation of IL-10 production by immune cells.
1576 *Nature Reviews. Immunology* 10, 170-181.

1577 Saviola, B., Bishai, W., Dr, M.D.P., Falkow, S., Rosenberg, E., Schleifer, K.-H.,
1578 Stackebrandt, E., 2006. *The Genus Mycobacterium--Medical, The Prokaryotes*. Springer
1579 New York, pp. 919-933.

1580 Scanga, C.A., Bafica, A., Feng, C.G., Cheever, A.W., Hieny, S., Sher, A., 2004. MyD88-
1581 deficient mice display a profound loss in resistance to Mycobacterium tuberculosis
1582 associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression.
1583 *Infection and Immunity* 72, 2400-2404.

1584 Schlesinger, L.S., 1996. Entry of Mycobacterium tuberculosis into mononuclear
1585 phagocytes. *Current Topics in Microbiology and Immunology* 215, 71-96.

1586 Schon, T., Elmberger, G., Negesse, Y., Pando, R.H., Sundqvist, T., Britton, S., 2004.
1587 Local production of nitric oxide in patients with tuberculosis. *The International Journal of*
1588 *Tuberculosis and Lung Disease: The Official Journal of the International Union Against*
1589 *Tuberculosis and Lung Disease* 8, 1134-1137.

1590 Scott-Browne, J.P., Shafiani, S., Tucker-Heard, G.s., Ishida-Tsubota, K., Fontenot, J.D.,
1591 Rudensky, A.Y., Bevan, M.J., Urdahl, K.B., 2007. Expansion and function of Foxp3-

1592 expressing T regulatory cells during tuberculosis. *The Journal of Experimental Medicine*
1593 204, 2159-2169.

1594 Sherman, D.R., Guinn, K.M., Hickey, M.J., Mathur, S.K., Zakel, K.L., Smith, S., 2004.
1595 *Mycobacterium tuberculosis* H37Rv: Delta RD1 is more virulent than *M. bovis* bacille
1596 Calmette-Guerin in long-term murine infection. *The Journal of Infectious Diseases* 190,
1597 123-126.

1598 Sherman, D.R., Mdluli, K., Hickey, M.J., Barry, C.E., Stover, C.K., 1999. AhpC,
1599 oxidative stress and drug resistance in *Mycobacterium tuberculosis*. *BioFactors* (Oxford,
1600 England) 10, 211-217.

1601 Srivastava, S., Ernst, J.D., 2014. Cell-to-cell transfer of *M. tuberculosis* antigens
1602 optimizes CD4 T cell priming. *Cell Host & Microbe* 15, 741-752.

1603 Stinear, T.P., Seemann, T., Harrison, P.F., Jenkin, G.A., Davies, J.K., Johnson, P.D.R.,
1604 Abdellah, Z., Arrowsmith, C., Chillingworth, T., Churcher, C., Clarke, K., Cronin, A.,
1605 Davis, P., Goodhead, I., Holroyd, N., Jagels, K., Lord, A., Moule, S., Mungall, K.,
1606 Norbertczak, H., Quail, M.A., Rabinowitsch, E., Walker, D., White, B., Whitehead, S.,
1607 Small, P.L.C., Brosch, R., Ramakrishnan, L., Fischbach, M.A., Parkhill, J., Cole, S.T.,
1608 2008. Insights from the complete genome sequence of *Mycobacterium marinum* on the
1609 evolution of *Mycobacterium tuberculosis*. *Genome Research* 18, 729-741.

1610 Stuehr, D.J., Marletta, M.A., 1987. Induction of nitrite/nitrate synthesis in murine
1611 macrophages by BCG infection, lymphokines, or interferon-gamma. *Journal of*
1612 *Immunology* (Baltimore, Md.: 1950) 139, 518-525.

1613 Sturgill-Koszycki, S., Schlesinger, P.H., Chakraborty, P., Haddix, P.L., Collins, H.L.,
1614 Fok, A.K., Allen, R.D., Gluck, S.L., Heuser, J., Russell, D.G., 1994. Lack of acidification
1615 in *Mycobacterium* phagosomes produced by exclusion of the vesicular proton-ATPase.
1616 *Science* 263, 678-681.

1617 Swaim, L.E., Connolly, L.E., Volkman, H.E., Humbert, O., Born, D.E., Ramakrishnan, L.,
1618 2006. *Mycobacterium Marinum* Infection of Adult Zebrafish Causes Caseating
1619 Granulomatous Tuberculosis and Is Moderated by Adaptive Immunity. *Infection and*
1620 *Immunity* 74, 6108-6117.

1621 Takaki, K., Ramakrishnan, L., Basu, S., 2018. A zebrafish model for ocular tuberculosis.
1622 *PLOS ONE* 13, e0194982.

1623 Taylor, J.L., Hattle, J.M., Dreitz, S.A., Troudt, J.M., Izzo, L.S., Basaraba, R.J., Orme,
1624 I.M., Matrisian, L.M., Izzo, A.A., 2006. Role for matrix metalloproteinase 9 in
1625 granuloma formation during pulmonary *Mycobacterium tuberculosis* infection. *Infect*
1626 *Immun* 74, 6135-6144.

1627 Taylor, M.W., Feng, G.S., 1991. Relationship between interferon-gamma, indoleamine
1628 2,3-dioxygenase, and tryptophan catabolism. *FASEB journal: official publication of the*
1629 *Federation of American Societies for Experimental Biology* 5, 2516-2522.

1630 Tobin, D.M., Roca, F.J., Oh, S.F., McFarland, R., Vickery, T.W., Ray, J.P., Ko, D.C.,
1631 Zou, Y., Bang, N.D., Chau, T.T.H., Vary, J.C., Hawn, T.R., Dunstan, S.J., Farrar, J.J.,
1632 Thwaites, G.E., King, M.-C., Serhan, C.N., Ramakrishnan, L., 2012. Host genotype-
1633 specific therapies can optimize the inflammatory response to mycobacterial infections.
1634 *Cell* 148, 434-446.

1635 Tobin, D.M., Vary, J.C., Ray, J.P., Walsh, G.S., Dunstan, S.J., Bang, N.D., Hagge, D.A.,
1636 Khadge, S., King, M.-C., Hawn, T.R., Moens, C.B., Ramakrishnan, L., 2010. The *lta4h*

1637 locus modulates susceptibility to mycobacterial infection in zebrafish and humans. *Cell*
1638 140, 717-730.

1639 Torraca, V., Tulotta, C., Snaar-Jagalska, B.E., Meijer, A.H., 2017. The chemokine
1640 receptor CXCR4 promotes granuloma formation by sustaining a mycobacteria-induced
1641 angiogenesis programme. *Sci Rep* 7, 45061.

1642 Tsao, T.C.Y., Huang, C.C., Chiou, W.K., Yang, P.Y., Hsieh, M.J., Tsao, K.C., 2002.
1643 Levels of interferon-gamma and interleukin-2 receptor-alpha for bronchoalveolar lavage
1644 fluid and serum were correlated with clinical grade and treatment of pulmonary
1645 tuberculosis. *The International Journal of Tuberculosis and Lung Disease: The Official*
1646 *Journal of the International Union Against Tuberculosis and Lung Disease* 6, 720-727.

1647 Tucker, E.W., Dooley, K.E., 2018. Preclinical tools for the evaluation of tuberculosis
1648 treatment regimens for children. *The International Journal of Tuberculosis and Lung*
1649 *Disease: The Official Journal of the International Union Against Tuberculosis and Lung*
1650 *Disease* 22, 7-14.

1651 Uplekar, M., Partnership, S.T.B., Organization, W.H., 2006. The Stop TB strategy :
1652 building on and enhancing DOTS to meet the TB-related Millennium Development Goals.

1653 Urdahl, K.B., Shafiani, S., Ernst, J.D., 2011. Initiation and regulation of T-cell responses
1654 in tuberculosis. *Mucosal Immunology* 4, 288-293.

1655 van der Vaart, M., Spaik, H.P., Meijer, A.H., 2012. Pathogen Recognition and
1656 Activation of the Innate Immune Response in Zebrafish, *Pathogen Recognition and*
1657 *Activation of the Innate Immune Response in Zebrafish. Advances in Hematology,*
1658 *Advances in Hematology* 2012, 2012, e159807.

1659 van Leeuwen, L.M., Boot, M., Kuijl, C., Picavet, D.I., van Stempvoort, G., van der Pol,
1660 S.M.A., de Vries, H.E., van der Wel, N.N., van der Kuip, M., van Furth, A.M., van der
1661 Sar, A.M., Bitter, W., 2018. Mycobacteria employ two different mechanisms to cross the
1662 blood-brain barrier. *Cell Microbiol* 20, e12858.

1663 van Leeuwen, L.M., van der Kuip, M., Youssef, S.A., de Bruin, A., Bitter, W., van Furth,
1664 A.M., van der Sar, A.M., 2014. Modeling tuberculous meningitis in zebrafish using
1665 *Mycobacterium marinum*. *Dis Model Mech* 7, 1111-1122.

1666 van Rie, A., Warren, R., Richardson, M., Victor, T.C., Gie, R.P., Enarson, D.A., Beyers,
1667 N., van Helden, P.D., 1999. Exogenous reinfection as a cause of recurrent tuberculosis
1668 after curative treatment. *The New England Journal of Medicine* 341, 1174-1179.

1669 Venkataswamy, M.M., Goldberg, M.F., Baena, A., Chan, J., Jacobs, W.R., Porcelli, S.A.,
1670 2012. In vitro culture medium influences the vaccine efficacy of *Mycobacterium bovis*
1671 BCG. *Vaccine* 30, 1038-1049.

1672 Verbon, A., Juffermans, N., Van Deventer, S.J., Speelman, P., Van Deutekom, H., Van
1673 Der Poll, T., 1999. Serum concentrations of cytokines in patients with active tuberculosis
1674 (TB) and after treatment. *Clinical and Experimental Immunology* 115, 110-113.

1675 Volkman, H.E., Clay, H., Beery, D., Chang, J.C.W., Sherman, D.R., Ramakrishnan, L.,
1676 2004. Tuberculous Granuloma Formation Is Enhanced by a *Mycobacterium* Virulence
1677 Determinant. *PLOS Biology* 2, e367.

1678 Volkman, H.E., Pozos, T.C., Zheng, J., Davis, J.M., Rawls, J.F., Ramakrishnan, L., 2010.
1679 Tuberculous granuloma induction via interaction of a bacterial secreted protein with host
1680 epithelium. *Science* 327, 466-469.

1681 Voskuil, M.I., Schnappinger, D., Visconti, K.C., Harrell, M.I., Dolganov, G.M., Sherman,
1682 D.R., Schoolnik, G.K., 2003. Inhibition of Respiration by Nitric Oxide Induces a

1683 Mycobacterium tuberculosis Dormancy Program. The Journal of Experimental Medicine
1684 198, 705-713.

1685 Vynnycky, E., Fine, P.E., 2000. Lifetime risks, incubation period, and serial interval of
1686 tuberculosis. American Journal of Epidemiology 152, 247-263.

1687 Walton, E.M., Cronan, M.R., Beerman, R.W., Tobin, D.M., 2015. The Macrophage-
1688 Specific Promoter mfap4 Allows Live, Long-Term Analysis of Macrophage Behavior
1689 during Mycobacterial Infection in Zebrafish. PLOS ONE 10, e0138949.

1690 Walton, E.M., Cronan, M.R., Cambier, C.J., Rossi, A., Marass, M., Foglia, M.D., Brewer,
1691 W.J., Poss, K.D., Stainier, D.Y.R., Bertozzi, C.R., Tobin, D.M., 2018. Cyclopropane
1692 Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and
1693 Mycobacterial Growth through Vegf Signaling. Cell Host Microbe 24, 514-525 e516.

1694 Wang, X.-F., Wang, H.-S., Wang, H., Zhang, F., Wang, K.-F., Guo, Q., Zhang, G., Cai, S.-
1695 H., Du, J., 2014. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance:
1696 Focus on macrophage polarization of THP-1 cells. Cellular Immunology 289, 42-48.

1697 Warner, D.F., 2015. Mycobacterium tuberculosis Metabolism. Cold Spring Harbor
1698 Perspectives in Medicine 5.

1699 Wayne, L.G., Sohaskey, C.D., 2001. Nonreplicating persistence of mycobacterium
1700 tuberculosis. Annual Review of Microbiology 55, 139-163.

1701 Weerdenburg Eveline, M., Abdallah Abdallah, M., Mitra, S., de Punder, K., van der Wel
1702 Nicole, N., Bird, S., Appelmelk Ben, J., Bitter, W., van der Sar Astrid, M., 2012. ESX5-
1703 deficient Mycobacterium marinum is hypervirulent in adult zebrafish. Cellular
1704 Microbiology 14, 728-739.

1705 Wen, Y., Fang, W., Xiang, L.-X., Pan, R.-L., Shao, J.-Z., 2011. Identification of Treg-
1706 like cells in Tetraodon: insight into the origin of regulatory T subsets during early
1707 vertebrate evolution. Cellular and molecular life sciences: CMLS 68, 2615-2626.

1708 Winslow, G.M., Cooper, A., Reiley, W., Chatterjee, M., Woodland, D.L., 2008. Early T-
1709 cell responses in tuberculosis immunity. Immunological Reviews 225, 284-299.

1710 Wolzak, N.K., Cooke, M.L., Orth, H., van Toorn, R., 2012. The changing profile of
1711 pediatric meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr 58,
1712 491-495.

1713 Xie, J., Hodgkinson, J.W., Katzenback, B.A., Kovacevic, N., Belosevic, M., 2013.
1714 Characterization of three Nod-like receptors and their role in antimicrobial responses of
1715 goldfish (*Carassius auratus* L.) macrophages to *Aeromonas salmonicida* and
1716 *Mycobacterium marinum*. Developmental & Comparative Immunology 39, 180-187.

1717 Yang, C.-S., Yuk, J.-M., Jo, E.-K., 2009. The Role of Nitric Oxide in Mycobacterial
1718 Infections. Immune Network : Official Journal of the Korean Society for Immunology
1719 and Biological Response Modifiers 9, 46-52.

1720 Yang, C.T., Cambier, C.J., Davis, J.M., Hall, C.J., Crosier, P.S., Ramakrishnan, L., 2012.
1721 Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of
1722 mycobacteria phagocytosed from infected macrophages. Cell Host Microbe 12, 301-312.

1723 Yoon, S., Mitra, S., Wyse, C., Alnabulsi, A., Zou, J., Weerdenburg, E.M., Sar, A.M.v.d.,
1724 Wang, D., Secombes, C.J., Bird, S., 2015. First Demonstration of Antigen Induced
1725 Cytokine Expression by CD4-1+ Lymphocytes in a Poikilotherm: Studies in Zebrafish
1726 (*Danio rerio*). PLOS ONE 10, e0126378.

1727 Yu, J., Tran, V., Li, M., Huang, X., Niu, C., Wang, D., Zhu, J., Wang, J., Gao, Q., Liu, J.,
1728 2012. Both phthiocerol dimycocerosates and phenolic glycolipids are required for
1729 virulence of *Mycobacterium marinum*. *Infect Immun* 80, 1381-1389.
1730 Yuasa, H.J., Takubo, M., Takahashi, A., Hasegawa, T., Noma, H., Suzuki, T., 2007.
1731 Evolution of vertebrate indoleamine 2,3-dioxygenases. *Journal of Molecular Evolution* 65,
1732 705-714.
1733 Zhang, X., Majlessi, L., Deriaud, E., Leclerc, C., Lo-Man, R., 2009. Coactivation of Syk
1734 kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties
1735 of neutrophils. *Immunity* 31, 761-771.
1736 Zhang, Y.J., Reddy, M.C., Ioerger, T.R., Rothchild, A.C., Dartois, V., Schuster, B.M.,
1737 Trauner, A., Wallis, D., Galaviz, S., Huttenhower, C., Sacchetti, J.C., Behar, S.M.,
1738 Rubin, E.J., 2013. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-
1739 mediated killing. *Cell* 155, 1296-1308.
1740
1741